Occurrence and transmission potential of asymptomatic and 1 presymptomatic SARS-CoV-2 infections: update of a living 2 systematic review and meta-analysis 3 4 Diana Buitrago-Garcia\*1,2 5 Aziz Mert Ipekci\*1 6 Leonie Heron \*1 7 8 Hira Imeri<sup>1</sup> Lucia Araujo-Chaveron<sup>3,4</sup> 9 10 Ingrid Arevalo-Rodriguez<sup>5</sup> Agustín Ciapponi<sup>6</sup> 11 12 Muge Cevik<sup>7</sup> Anthony Hauser<sup>1</sup> 13 14 Muhammad Irfanul Alam<sup>3</sup> 15 Kaspar Meili<sup>8</sup> 16 Eric A. Meyerowitz<sup>9</sup> Nirmala Prajapati<sup>10</sup> 17 Xueting Qiu<sup>11</sup> 18 Aaron Richterman<sup>12</sup> 19 20 William Gildardo Robles-Rodríguez<sup>13</sup> Shabnam Thapa<sup>14</sup> 21 Ivan Zhelyazkov<sup>15</sup> 22 23 Georgia Salanti<sup>1</sup> 24 Nicola Low<sup>1</sup> 25 \* These authors contributed equally to this work 26 27 28 29 30 31

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 33 1. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
- 34 2. Graduate School of Health Sciences, University of Bern, Bern, Switzerland
- 35 3. EHESP French School of Public Health La Plaine St Denis, Rennes, France
- 36 4. Institut Pasteur, Paris, France
- 37 5. Clinical Biostatistics Unit, Hospital Universitario Ramon y Cajal, IRYCIS, CIBER of
- 38 Epidemiology and Public Health, Madrid, Spain
- 39 6. Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina
- 40 7. Division of Infection and Global Health Research, School of Medicine, University of St.
- 41 Andrews, Fife, Scotland, United Kingdom
- 42 8. Department of Epidemiology and Global Health, Umeå University, Umeå, Sweden
- 9. Division of Infectious Diseases, Montefiore Medical Center, Bronx, New York, United States of 43
- 44 America
- 45 10. Université Paris-Saclay, Paris, France
- 11. Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard TH Chan 46
- 47 School of Public Health, Boston, United States of America
- 12. Division of Infectious Diseases, University of Pennsylvania, Philadelphia, United States of 48
- 49 America
- 13. Fundación Universitaria de Ciencias de la Salud. Bogotá, Colombia. 50
- 51 14. Manchester Centre for Health Economics, University of Manchester, Manchester, United
- 52 Kingdom

- 15. University of Sheffield, Sheffield, United Kingdom 53
- 55 Word counts: Abstract, 468; main text 4945; 2 tables; 3 figures; 191 references
- 56 Supplementary material: 2 text files; 5 tables; 5 figures; 1 checklist; 2 appendices
- 57 Corresponding author: nicola.low@ispm.unibe.ch

**ABSTRACT** 58 59 **BACKGROUND** Debate about the level of asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-60 61 CoV-2) infection continues. The amount of evidence is increasing and study designs have changed 62 over time. We updated a living systematic review to address three questions: (1) Amongst people who become infected with SARS-CoV-2, what proportion does not experience symptoms at all during 63 64 their infection? (2) What is the infectiousness of asymptomatic and presymptomatic, compared with symptomatic, SARS-CoV-2 infection? (3) What proportion of SARS-CoV-2 transmission in a 65 66 population is accounted for by people who are asymptomatic or presymptomatic? METHODS AND FINDINGS 67 68 The protocol was first published on 1 April 2020 and last updated on 18 June 2021. We searched PubMed, Embase, bioRxiv and medRxiv, aggregated in a database of SARS-CoV-2 literature, most 69 recently on 6 July 2021. Studies of people with PCR-diagnosed SARS-CoV-2, which documented 70 71 symptom status at the beginning and end of follow-up, or mathematical modelling studies were 72 included. Studies restricted to people already diagnosed, of single individuals or families, or without sufficient follow-up were excluded. One reviewer extracted data and a second verified the extraction, 73 74 with disagreement resolved by discussion or a third reviewer. Risk of bias in empirical studies was 75 assessed with a bespoke checklist and modelling studies with a published checklist. All data syntheses 76 were done using random effects models. Review question (1): We included 130 studies. Heterogeneity was high so we did not estimate a mean proportion of asymptomatic infections overall 77 78 (interquartile range 14-50%, prediction interval 2-90%), or in 84 studies based on screening of defined populations (interquartile range 20-65%, prediction interval 4-94%). In 46 studies based on 79 80 contact or outbreak investigations, the summary proportion asymptomatic was 19% (95% CI 15-25%, 81 prediction interval 2-70%). (2) The secondary attack rate in contacts of people with asymptomatic 82 infection compared with symptomatic infection was 0.32 (95% CI 0.16-0.64, prediction interval 0.11-83 0-95, 8 studies). (3) In 13 modelling studies fit to data, the proportion of all SARS-CoV-2 84 transmission from presymptomatic individuals was higher than from asymptomatic individuals.

Limitations of the evidence include high heterogeneity and high risks of selection and information

bias in studies that were not designed to measure persistently asymptomatic infection, and limited information about variants of concern or in people who have been vaccinated.

CONCLUSIONS

Based on studies published up to July 2021, most SARS-CoV-2 infections were not persistently asymptomatic and asymptomatic infections were less infectious than symptomatic infections.

Summary estimates from meta-analysis may be misleading when variability between studies is extreme and prediction intervals should be presented. Future studies should determine the asymptomatic proportion of SARS-CoV-2 infections caused by variants of concern and in people with immunity following vaccination or previous infection. Without prospective longitudinal studies with methods that minimise selection and measurement biases, further updates with the study types included in this living systematic review are unlikely to be able to provide a reliable summary estimate of the proportion of asymptomatic infections caused by SARS-CoV-2.

REVIEW PROTOCOL: Open Science Framework (https://osf.io/9ewys/)

**AUTHOR SUMMARY** 

- Why was this study done? 101
- The proportion of people who will remain asymptomatic throughout the course of infection with 102
- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 103
- 2019 (covid-19), is debated. 104
- Studies that assess people at just one time point overestimate the proportion of true asymptomatic 105
- infection because those who go on to develop covid-19 symptoms will be wrongly classified as 106
- asymptomatic, but other types of study might underestimate the proportion if, for example, people 107
- with symptoms are more likely to be included in a study population. 108
- 109 The number of published studies about SARS-CoV-2 is increasing continuously, types of studies
- are changing and, since 2021, vaccines have become available, and variants of concern have 110
- 111 emerged.

131

100

#### What did the researchers do and find? 112

- 113 We updated a living systematic review through 6 July 2021, using automated workflows that
- speed up the review processes, and allow the review to be updated when relevant new evidence 114
- 115 becomes available.
- 116 In 130 studies, we found an interquartile range of 14-50% (prediction interval 2-90%) of people
- with SARS-CoV-2 infection that was persistently asymptomatic; owing to heterogeneity, we did 117
- 118 not estimate a summary proportion.
- Contacts of people with asymptomatic SARS-CoV-2 infection are less likely to become infected 119
- 120 than contacts of people with symptomatic infection (risk ratio 0.38, 95% CI 0.16-0.64, prediction
- 121 interval 0.11-0.95, 8 studies).

#### What do these findings mean? 122

- 123 Up to mid-2021, most people with SARS-CoV-2 were not persistently asymptomatic and
- 124 asymptomatic infection was less infectious than symptomatic infection.
- 125 In the presence of high between-study variability, summary estimates from meta-analysis may be
- misleading and prediction intervals should be presented. 126
- Future studies about asymptomatic SARS-CoV-2 infections caused by variants of concern and in 127
- people with immunity following vaccination or previous infection should be specifically 128
- 129 designed, using methods to minimise biases in the selection of study participants and in
- 130 ascertainment, classification and follow-up of symptom status.

Introduction

132133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

There is ongoing debate about the true proportion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that remains asymptomatic [1]. A well-recognised source of overestimation arises when people without symptoms at the time of testing are reported as having asymptomatic infection, with such cross-sectional studies often reporting percentages of 80% or more [2,3]. These studies overestimate the proportion of persistently asymptomatic infection because they misclassify people with so-called presymptomatic infection, who will develop symptoms of coronavirus disease 2019 (COVID-19) if reassessed after an adequate follow-up period [1]. Other sources of bias can result in over- or underestimation of the proportion with persistent asymptomatic infections, even when participants are adequately followed up [1]. For example, studies that assess a limited range of symptoms could overestimate the proportion asymptomatic through misclassification if they do not ask participants about all possible symptoms. Since COVID-19 was first identified as a viral pneumonia, the spectrum of symptoms has grown to include gastro-intestinal symptoms and disturbances of smell and taste [1]. On the other hand, selection bias would be expected to underestimate the proportion with asymptomatic SARS-CoV-2 if people with symptoms are more likely to be tested for SARS-CoV-2 infection than those without symptoms [4]. Accurate estimates of the proportions of true asymptomatic and presymptomatic infections are needed to determine the balance and range of control measures [5]. Recognition of asymptomatic and presymptomatic infections showed the importance of control measures such as physical distancing, active case-finding through testing of asymptomatic people [6] and the need for rapid quarantine [7] in the first waves. Since late 2020, vaccines have become available [8] and several SARS-CoV-2 variants of concern have spread internationally, with varying viral characteristics [9]. The number of published studies about SARS-CoV-2 is also increasing continuously and the types of published studies are also changing [10], including the designs of studies about asymptomatic infection. In systematic reviews of studies published to April 2021, reported point estimates from random effects meta-analysis models range from 17 to 41% [11-16]. Authors of these reviews typically report values of the I<sup>2</sup> statistic >90 [17,18], but heterogeneity is often not explored in detail and prediction

intervals, which give information about sampling error and variability between studies, are recommended but rarely reported[17,19,20]. In this fifth update of our living systematic review [21] we aimed to improve and understand the changing evidence over time for three review questions: (1) Amongst people who become infected with SARS-CoV-2, what proportion does not experience symptoms at all during their infection? (2) What is the infectiousness of people with asymptomatic and presymptomatic, compared with symptomatic SARS-CoV-2 infection? (3) What proportion of SARS-CoV-2 transmission is accounted for by people who are either asymptomatic throughout infection, or presymptomatic?

### Methods

We conducted an update of a living systematic review, a systematic review that provides an online summary of findings and is updated when relevant new evidence becomes available [22]. The protocol, which describes modifications for each update, was first published on 1 April 2020 and amended for this version on 18 June 2021, (<a href="https://osf.io/9ewys/">https://osf.io/9ewys/</a>). Previous versions have been posted as preprints [21,23] and published as a peer-reviewed article [12]. We report our findings according to statements on preferred reporting items for systematic reviews and meta-analyses 2020 (S1 PRISMA 2020 Checklist) [24] and on synthesis without meta-analysis in systematic reviews (SWiM) [25]. Ethics committee review was not required for this review. Box 1 shows our definitions of symptoms, asymptomatic infection and presymptomatic status.

# Box 1. Definitions of symptoms and symptom status in a person with SARS-CoV-2 infections

**Symptoms:** symptoms that a person experiences and reports. We used the authors' definitions. We searched included manuscripts for an explicit statement that the study participant did not report symptoms that they experienced. Some authors defined 'asymptomatic' as an absence of self-reported symptoms. We did not include clinical signs observed or elicited on examination.

**Asymptomatic infection:** a person with laboratory-confirmed SARS-CoV-2 infection, who has no symptoms, according to the authors' report, at the time of first clinical assessment and had no symptoms at the end of follow-up. The end of follow-up was defined as any of the following: virological cure, with one or more negative RT-PCR test results; follow-up for 14 days or more after the last possible exposure to an index case; follow-up for seven days or more after the first RT-PCR positive result.

**Presymptomatic:** a person with laboratory-confirmed SARS-CoV-2 infection, who has no symptoms, according to the authors' report, at the time of first clinical assessment, but who

developed symptoms by the end of follow-up. The end of follow-up was defined as any of the following: virological cure, with one or more negative RT-PCR test results; follow-up for 14 days or more after the last possible exposure to an index case; follow-up for seven days or more after the first RT-PCR positive result.

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

Information sources and search We conducted the first search on 25 March 2020 and updated it on 20 April 2020, 10 June 2020, 2 February 2021 and, for this update, 6 July 2021. We searched the COVID-19 living evidence database [26], which uses automated workflow processes to: (1) aggregate simultaneous daily searches of four electronic databases (Medline, PubMed, Ovid Embase, bioRxiv and medRxiv), using medical subject headings and free-text keywords for SARS-CoV-2 infection and COVID-19; (2) de-duplicate the records; (3) tag records that are preprints; and (4) allow searches of titles and abstracts using Boolean operators. We used the search function to identify studies of asymptomatic or presymptomatic SARS-CoV-2 infection using a search string of medical subject headings and free text keywords (S1 Text). We also examined articles suggested by experts and the reference lists of retrieved studies. Reports were planned to be updated at 3-monthly intervals, with continuously updated searches. Eligibility criteria We included studies, in any language, of people with SARS-CoV-2 diagnosed by RT-PCR that documented follow-up and symptom status at the beginning and end of follow-up or investigated the contribution to SARS-CoV-2 transmission of asymptomatic or presymptomatic infection. We included contact tracing and outbreak investigations, cohort studies, case-control studies, and mathematical modelling studies. We amended eligibility criteria after the third version of the review [12] in two ways. First, we excluded studies that only reported the proportion of presymptomatic SARS-CoV-2 because the settings and methods of these studies were very different and their results were too heterogeneous to summarise [12]. Second, we aimed to reduce the risk of bias from studies with inclusion criteria based mainly on people with symptoms, which would systematically underestimate the proportion of people with asymptomatic infection. We therefore excluded the following study types: case series restricted to people already diagnosed and studies that did not report the number of people tested for SARS-CoV-2, from whom the study population was derived. We also excluded case reports and contact investigations of single individuals or families, and any study

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

without sufficient follow-up (Box 1). Where data from the same study population were reported in multiple records, we extracted data from the most comprehensive report. Study selection and data extraction Reviewers, including crowdsourced trained volunteers, worked in pairs to screen records using an application programming interface in the electronic data capture system (REDCap, Vanderbilt University, Nashville, TN, USA). One reviewer applied eligibility criteria to select studies and a second reviewer verified all included and excluded studies. We reported the process in a flow diagram, adapted for living systematic reviews [27] (S1 Fig). The reviewers determined which of the three review questions each study addressed. One reviewer extracted data using a pre-piloted extraction form in REDCap and a second reviewer verified the extracted data. For both study selection and data extraction, a third reviewer adjudicated on disagreements that could not be resolved by discussion. We contacted study authors for clarifications. The extracted variables included, study design, country and/or region, study setting, population, age, sex, primary outcomes and length of follow-up (full list of variables in S1 Appendix). We extracted raw numbers of individuals with an outcome of interest and relevant denominators from empirical studies. From statistical and mathematical modelling studies we extracted proportions and 95% credibility intervals. The primary outcomes for each review question were (1) the proportion of people with asymptomatic SARS-CoV-2 infection who did not experience symptoms at all during follow-up; (2) secondary attack rate from asymptomatic or presymptomatic index cases, compared with symptomatic cases; (3) model-estimated proportion of SARS-CoV-2 transmission accounted for by people who are asymptomatic or presymptomatic. Risk of bias in included studies After the third version of the review [12], we developed a new tool to assess the risk of bias because the study designs of included studies have changed. In previous versions, we used items from tools to assess case series [28] and the prevalence of mental health disorders [29]. The new tool assessed possible biases in studies of prevalence in general and COVID-19 in particular [4,30]. We developed

signalling questions in the domains of selection (two items), information (three items) and selective

232

233

234235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

reporting (one item) biases (S2 Text). For mathematical modelling studies, we used a checklist for assessing relevance and credibility [31]. Two authors independently assessed the risk of bias, using a customised online tool. A third reviewer resolved disagreements. Synthesis of the evidence The data extracted and the code used to display and synthesise the results are publicly available: https://github.com/leonieheron/LSR\_Asymp\_v4. We used the metaprop, metabin and metafor functions from the meta package (version 4.11-0) [32] and the ggplot2 package (version 3.3.5) in R (version 3.5.1). The 95% confidence intervals (CI) for each study were estimated using the Clopper-Pearson method [33]. For review question 1, in contact or outbreak investigations, we subtracted the index cases from the total with SARS-CoV-2 infection, because these people were likely to have been identified because of their symptoms and their inclusion might lead to underestimation of the asymptomatic proportion [16]. For all meta-analyses, we used stratified random effects models. Where a meta-analysis was not done, we present the interquartile range (IQR) and describe heterogeneity visually in forest plots, ordered by study sample size [25]. We calculated the I<sup>2</sup> statistic, which is the approximate proportion of between-study variability that is due to heterogeneity other than chance and  $\tau^2$ , the between-study variance. We calculated 95% prediction intervals for all summary estimates, to give a likely range of proportions that would have been obtained in hypothetical studies conducted in similar settings [17,19,20]. We did subgroup analyses for prespecified characteristics of study design, setting and risk of bias and post-hoc analyses according to age group and geographic region, comparing groups using a  $\chi^2$  test. We used meta-regression for posthoc analyses examining associations with study size and publication date. To compare our findings with other studies, we extracted the raw data from five systematic reviews [11,13-16] and calculated prediction intervals [17]. For review question 2, as a measure of infectiousness, we calculated the secondary attack rate as the number of SARS-CoV-2-infected contacts as a proportion of all close contacts ascertained. For each included study, we compared the secondary attack rate from asymptomatic or presymptomatic index cases with that from symptomatic cases in the same study. If there were no events in a group, we added 0.5 to each cell in the 2x2 table. We did not account for

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

potential clustering of contacts because the included studies did not report the number and size of infection clusters consistently. We used the Hartung-Knapp method for random effects meta-analysis to estimate a summary risk ratio (with 95% CI) [34]. For review question 3, we reported the findings descriptively because of large differences between study settings, methods and results. We did not construct funnel plots to examine bias across studies because their utility in studies reporting on proportions is not clear. Results The searches for studies about asymptomatic or presymptomatic SARS-CoV-2, on 25 March, 20 April and 10 June 2020 and 2 February and 6 July 2021 resulted in 89, 230, 688, 4,213 and 3,018 records for screening, respectively (S1 Fig). Owing to changes in eligible study designs, this update excludes 67 articles from earlier versions (S1 Table). We included a total of 146 studies addressing one or more review questions; 130 empirical studies that estimate the proportion of people with asymptomatic SARS-CoV-2 (summarised in Table 1 and S2 Table) [35-164], eight studies reporting on secondary attack rates [35,81,131,142,165-168], and 13 mathematical modelling studies [7,165,169-179]. At the time of the search on 6 July 2021, five records were preprints. We checked the publication status on 14 March 2022 and all were still preprints [61,62,88,169,171]. The review period from 1 January 2021 onwards includes 52 publications, three of which collected data during the period when the alpha variant of concern [85,125,133] had been described and vaccines were being introduced. Proportion of people with asymptomatic SARS-CoV-2 infection The 130 studies reported on 28,426 people with SARS-CoV-2 infection (11,923 defined as having asymptomatic infection) in 42 countries [35-164] (Table 1, S3Table). Amongst all 130 included studies, 88 studies used more than one method of follow-up to ascertain asymptomatic status (Table 1, S2 Table). Only 22 of 130 studies reported the median or mean age [38,47,70,76,77,83,85,95,99,119-121,124,126,128,133,134,139,143,146,152,164] and only five studies included children only [65,67,110,115,118]. Only 31 studies reported the sex of people with asymptomatic SARS-CoV-2 (Table 1, S2 Table) [38,47,51,53,70,71,75,76,83,85,95,99,107,119-122,124,126,128,133,134,139,143,146,147,150,153,158,162,164]. The types of included studies

286

287

288

289

290

291

292

293 294 changed across the five versions of the review. In the first version [23], six of nine studies were contact tracing investigations of single-family clusters. In this version, two main types of study design generated the study populations of people with SARS-CoV-2: contact tracing or outbreak investigation methods were used to identify and test potentially infected contacts (46 studies, referred to as contact and outbreak investigations); and studies that involved screening of a defined group of people in settings in the community, institutions, such as long-term care facilities, or occupational groups (84 studies, referred to as screening studies).

Table 1. Summary of characteristics of studies reporting on proportion of asymptomatic SARS-**CoV-2 infections (review question 1)** 

	Study design and setting					
	Contact	Outbreak investigation	Screenir	studies		
	investigation		Community	Institutional	Occupational	
Total studies, n	13	33	23	43	18	130
Publication date						
Jan 2020 – Jun 2020	5	9	3	3	4	24
Jul 2020 – Dec 2020	5	17	11	17	6	56
Jan 2021 onward	3	7	9	23	8	50
Region <sup>b</sup>						
Africa	0	2	2	1	1	6
Americas	5	10	4	19	7	45
South-East Asia	0	3	2	2	1	7
Europe	2	13	7	18	5	45
Eastern Mediterranean	0	0	3	2	2	8
Western Pacific	6	6	5	1	2	19
Follow-up method <sup>c</sup>						
14 days after last possible	7	11	2	3	4	27
exposure						
≥7 days after diagnosis	11	27	19	35	16	108
Until negative RT-PCR result	2	4	9	12	6	33
Two or more follow-up methods	8	21	17	28	14	88
Age range of study participants						
Children (<18 years)	1	1	0	3	0	5
Adults (18 – 65 years)	3	10	9	16	14	52
Older adults (>65 years)	0	7	0	6	0	13
All ages	7	14	10	15	2	48
No information about age	2	1	4	3	2	12
Total with SARS-CoV-2 infection, n	1076	4910	10652	8921	2867	28426
Asymptomatic SARS-CoV-2 infections	264	1409	6007	3658	585	11923
Gender of asymptomatic cases <sup>c</sup>						
Male	1	33	1419	30	16	1499
Female	0	32	589	313	26	960

296

297

298 299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; Jan, January; Jun, June; Jul, July; Dec, December <sup>a</sup> S2 Table reports the characteristics of each study included; <sup>b</sup> World Health Organization regions; <sup>c</sup> Studies could have more than one method of follow-up (S2 Table); <sup>d</sup> 99 studies did not report the gender of asymptomatic cases. Between-study heterogeneity was considerable, so we did not estimate a mean proportion of asymptomatic infections overall, or for screening studies (Fig 1). The IQR of estimates for all 130 included studies (141 clusters) was 14-50% (prediction interval 2-90%). In 46 studies enrolling people found through contact or outbreak investigations, for example in long-term care facilities, in aeroplanes, or on cruise ships, we estimated a summary estimate for the proportion asymptomatic (19%, 95% CI 15-25%, prediction interval 2-70%, IQR 8-37%). The estimated proportions of asymptomatic SARS-CoV-2 infections were similar in studies of contact investigations (16%, 95% CI 9-27%, IQR 8-38%, 13 studies) and outbreak investigations (20%, 95% CI 15-28%, IQR 8-38%, 33 studies) (S2 Fig). In 84 screening studies, the IQR for estimates from individual studies was 20-65% and the prediction interval was 4-94% [41-48,50-54,56,58-63,67,69-71,73,74,79,83,86,88-97,99-101,103-105, 107, 109, 110, 114-117, 119, 120, 122, 124-126, 128, 130, 133-138, 143-145, 147, 150-156, 158-164]. The ranges of estimates were similar in three settings in which screening studies were conducted; people in a community setting (23 studies, IQR 20-53%, prediction interval 2-96%), institutional settings such as nursing homes (43 studies, IQR 26-67%, prediction interval 5-93%), and occupational settings such as amongst groups of healthcare workers (18 studies, IQR 17-64%, prediction interval 3-95%) (S2 Fig). Three studies had data collection periods from 1 January 2021. In two nursing home outbreaks, 3/4 SARS-CoV-2 infections in partially vaccinated residents [133] and 13/14 infections (with the alpha variant) [85] in full vaccinated residents were asymptomatic. One study among healthcare workers did not report on symptom status according to vaccination or variant of concern but found that 76/155 (49%) with reinfection compared with 273/1704 (17%) with primary infection were asymptomatic [125].




Figure 1. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection, stratified by study design. In contact and outbreak investigations, the summary estimate for meta-analysis was 19% (15-25%) and the interquartile range (IQR) was 8-37%. In screening studies, the IQR was 20-65%. Across all studies, the IQR was 14-50%. The x-axis displays proportions. The red bar shows the prediction interval below each group of studies, with the prediction interval for all studies at the bottom of the forest plot. Where more than one cluster was reported, clusters are annotated with [cluster identity].

326

327

328

329


330

331

332

333

334



337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

Risk of bias in individual studies There were risks of bias in all types of empirical studies (S3 Fig). In pre-specified subgroup analyses according to risk of bias domains (S4 Table2), statistical heterogeneity remained very high ( $I^2 \ge 84\%$ ) and the prediction intervals remained wide. In screening studies, the summary proportion in was lower in studies judged to be at low risk of information bias in the assessment of symptoms (29%, 95% CI 20-42%) than in studies at unclear or high risk of bias (47%, 95% CI 37-57%) (p=0.03, test for subgroup differences). For all other domains, estimates of the proportion asymptomatic were not associated with the assessment of the risk of bias. Factors associated with proportion of asymptomatic SARS-CoV-2 Table 2 shows analyses for factors pre-specified in the protocol and post-hoc (Table 2). Study design and setting was pre-specified and explained 16% of the variance in heterogeneity; estimates ranged from 16% (8-29%) for contact investigations to 45% (35-56%) for screening studies in institutional settings (S2 Fig). The date of publication was associated with the estimate of the proportion asymptomatic (S4 Fig), increasing in more recent publications (p 0.03), although this only explained 4% of the variance in heterogeneity. There was some evidence of variability in different world regions (p=0.06), explaining 9% of the heterogeneity. Sample size and age range of the study participants did not appear to influence the estimated asymptomatic proportion. In three systematic reviews that we reanalysed, prediction intervals were: 1-83% (241 studies [14]); 4-97% (95 studies [15]); and 3-89% (170 studies [16]). I<sup>2</sup> values were between 94% and 99% (S2 Appendix).

Table 2. Summary of findings of subgroup and meta-regression analyses of factors associated with the proportion of asymptomatic SARS-CoV-2 infections

Variable	Clustersa	Proportion at the reference value (95% CI)	τ <sup>2 b</sup>	p value (subgroup difference/ intercept)	Heterogeneity variance explained <sup>c</sup>
Reference	141	0.32 (0.27–0.38)	2.19	-	-
Study design and setting <sup>d</sup>		I		I	
Contact investigation	13	0.16 (0.08; 0.29)	1.87	<0.001	16%
Outbreak investigation	40	0.20 (0.14; 0.28)			
Screening: community	24	0.39 (0.26; 0.53)			
Screening: institutional	46	0.45 (0.35; 0.56)			
Screening: occupational	18	0.41 (0.26; 0.59)			
Age group <sup>e</sup>					
All ages	57	0.28 (0.21-0.37)	2.11	0.38	4%
Adults (18-65 years)	52	0.36 (0.27-0.47)			
Older adults (>65 years) only	14	0.25 (0.13-0.44)			
Children (<18 years) only	5	0.27 (0.09-0.58)			
Not reported	13	0.45 (0.27-0.66)			
Geographic region <sup>e f</sup>					
Americas	47	0.37 (0.27-0.47)	2.00	0.06	9%
Europe	52	0.24 (0.17-0.33)			
Western Pacific	20	0.35 (0.21-0.51)			
SE Asia	8	0.22 (0.09-0.43)			
East Mediterranean	8	0.59 (0.33-0.81)			
Africa	6	0.47 (0.22-0.74)			
Selection bias <sup>a d</sup>					
Low risk	54	0.34 (0.25-0.44)	2.19	0.67	0%
Unclear/high risk	87	0.31 (0.25-0.39)			
Information bias, assessment of s		. ,		1	I
Low risk	33	0.25 (0.16-0.36)	2.15	0.14	2%
Unclear/high risk	108	0.35 (0.28-0.42)			
Information bias, misclassificatio					
Low risk	107	0.32 (0.25-0.38)	2.19	0.65	0%
Unclear/ high risk	34	0.35 (0.24-0.47)			
Selective reporting bias <sup>a d</sup>		0.00 (0.2 : 0.17)			
Low risk	126	0.33 (0.27-0.40)	2.17	0.37	1%
Unclear/ high risk	15	0.25 (0.13-0.43)			
Sample size <sup>g</sup>					
Proportion at sample size 50	_	0.29 (0.14-0.51)	1.91	0.06	13%
Proportion at sample size 120	-	0.31 (0.24-0.39)			-573
Proportion at sample size200	_	0.32 (0.24-0.40)	1		
Publication date	1	(3.2 : 33)	1	1	1
Reference (first date, 19 Feb 2020)	_	0.21 (0.13–0.32)	2.09	<0.001	4%
Coefficient	_	0.50 (0.50–0.50)			
Cocincion		0.50 (0.50 0.50)			

358 CI, confidence interval

363 364

356

357

359 <sup>a</sup> Total number of studies, 130; independent within-study clusters counted individually;

<sup>c</sup> Formula for proportion of heterogeneity variance explained,  $\frac{\tau_{unadjusted}^2 - \tau_{adjusted}^2}{\tau_{unadjusted}^2}$ 361

<sup>d</sup> Pre-specified analysis in review protocol 362

<sup>e</sup> Subgroup analysis not specified in review protocol

<sup>f</sup> World Health Organization regions;

<sup>&</sup>lt;sup>b</sup> Common heterogeneity parameter estimated within each subgroup; 360

<sup>g</sup> Prevalence estimated using the meta-regression model for the approximate values of the median (n=46), the mean (n=202) and the third quartile (n=126) of study sample sizes.

365

366

367

368

369

370

371

372

373

374

375

376

377 378

379

380

381

382

383

Infectiousness of people with asymptomatic or presymptomatic SARS-CoV-2 Eight studies provided data to calculate and to compare secondary attack rates by symptom status of the index case (Fig 2) [35,81,131,142,165-168]. Seven studies compared the secondary attack rate from asymptomatic with symptomatic index cases (summary risk ratio 0.32 (95% CI 0.16-0.64, prediction interval 0.11-0.95) [81,131,142,165-167]. One study compared asymptomatic with presymptomatic index cases (summary risk ratio 0.19, 95% CI 0.02-1.46) [35] and four studies compared presymptomatic with symptomatic index cases (summary risk ratio 1.00 (95% CI 0.37-2.71, prediction interval 0.11-9.12) [81,142,166,167]. The risk of information bias, specifically in symptom assessment, was judged to be high or unclear in five of the eight studies included (S3 Fig).




Figure 2. Forest plot of the secondary attack rate of SARS-CoV-2 infections comparing infections in contacts of asymptomatic and presymptomatic index cases with infections in contacts of symptomatic cases. The RR is on a logarithmic scale. The diamonds show the summary estimate and its 95% confidence interval. The red bar shows the prediction interval. CI, confidence interval; E, number of secondary transmission events; N, number of close contacts; RR, risk ratio; Symp. symptomatic individuals.

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404


405

406

407

408

Contribution of asymptomatic and presymptomatic infection to SARS-CoV-2 transmission We included 13 mathematical modelling studies (Fig 3, S5 Table) [7,165,169-179]. The models in nine studies were informed by analyses of data from contact investigations in China, South Korea, Singapore, and from an outbreak on the *Diamond Princess* cruise ship, using data to estimate the serial interval or generation time [7,165,170,172,173,176-179]. In three studies the authors did not analyse any original data sources [169,174,175]. Estimates of the contributions of both asymptomatic and presymptomatic infections SARS-CoV-2 transmission were very heterogeneous. For asymptomatic SARS-CoV-2 infection, four studies contributed five estimates [7,171,175,177]. In three studies, the estimates suggested a contribution to SARS-CoV-2 transmission of asymptomatic infection of less than 15%. One study estimated a higher proportion (69%, 95% CrI 20-85%) with a wide credibility interval [177] (Fig 3). The estimates have large uncertainty intervals, and the disparate predictions result from differences in the proportion of asymptomatic infections and relative infectiousness of asymptomatic infection. We included 12 studies providing 16 estimates of the contribution of presymptomatic transmission [7,165,169,170,172-179]. The models examined a range of epidemic settings and used different assumptions about the durations and distributions of infection parameters such as incubation period, generation time and serial interval (S5 Table). In seven studies, point estimates for the estimated contribution of presymptomatic infection to all SARS-CoV-2 transmission in at least one reported scenario were 40% or greater [7,169,170,172,173,175,176] (Fig 3). In one study that estimated a contribution of <1% [174], the model-fitted serial interval was longer than observed in empirical studies. The credibility of most modelling studies was limited by the absence of external validation and of uncertainty intervals for the estimates cited. (S5 Fig). The estimates from studies that relied on data from different published sources that might not have been compatible were assessed as providing low quality evidence (S5 Table).



**Figure 3.** Forest plot of proportion of SARS-CoV-2 infection resulting from asymptomatic or presymptomatic transmission. For studies that report outcomes in multiple settings or with alternative assumptions, these are annotated in brackets. CI, confidence interval; SI, serial interval.

### Discussion

## Summary of main findings

1) For all 130 included studies, the IQR for the proportion of asymptomatic SARS-CoV-2 was 14-50%, prediction interval 2-90%) and for 84 studies based on screening of defined populations, IQR 20-65% (prediction interval 4-94%). In 46 studies that identified participants through contact tracing of index cases and outbreak investigations, the summary proportion from meta-analysis was 19% (95% CI 15-25%, prediction interval 2-70%). 2) The risk ratio for the secondary attack rate from asymptomatic compared with symptomatic infections was 0.38 (95% CI 0.16-0.64, prediction interval 0.11-0.95) and for presymptomatic infections compared with symptomatic infection was 1.00 (95% CI 0.37-2.71, prediction interval 0.11-9.12). 3) In mathematical modelling studies, estimated proportions of all SARS-CoV-2 infections that result from transmission from asymptomatic individuals were mostly below 15%, and from presymptomatic individuals mostly higher than 40%.

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

Evidence about asymptomatic infections caused by variants of concern, or with immunity following infection or vaccination, is limited. Strengths and weaknesses of the living systematic review methods A strength of the methodology of this review is the transparent reporting, with openly available data and changes over different versions reported in the protocol. Our inclusion criteria attempted to reduce risks of bias and we developed a new tool to address potential biases in the studies included in this review. In contact investigations, we subtracted index cases from the total number of people with SARS-CoV-2 to avoid underestimation of the proportion asymptomatic [16]. We examined heterogeneity in detail and, as a result of the wide prediction interval, we chose not to report an overall summary estimate [18,25]. A limitation of the methods for this living systematic review is that this update only includes published studies up to 6 July 2021. This covers the period when vaccines started to be rolled out and the alpha variant of concern became dominant in high-income countries. Although we made extensive efforts to comply with the planned 3-monthly updates, with weekly searches and a continuous process of screening, data extraction and risk of bias assessment, the pace of publications about SARS-CoV-2 exceeds the capacity of our crowd of reviewers [10,26]. Our decision to include preprints compensates for some of the delay because these articles appear sooner than peer-reviewed publications. In reviews of observational epidemiological studies, search terms are broad so the number of studies that needs to be screened is high, but the yield of included studies is low. The four databases that we searched are not comprehensive, but they cover the majority of publications and we do not believe that we have missed studies that would change our conclusions. We have also not considered the possible impact of false negative RT-PCR results, which might be more likely to occur in asymptomatic infections [180] and would underestimate the proportion of asymptomatic infections [181]. Comparison with other reviews and interpretation The type of studies that provide estimates of the proportion of asymptomatic SARS-CoV-2 infections and heterogeneity between them has changed over the course of the pandemic. In our living systematic review, the prediction interval has widened from 23-37% in studies published up to 25 March 2020 [23], to 3-67% up to June 2020 [12], 2-89% up to 2 February 2021 [21] and remains at 2-

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

90% up to 6 July. We found three systematic reviews, in which authors reported restriction to studies with adequate follow-up (S2 Appendix) [11,13,16]. In two of the reviews, authors also applied criteria to reduce the risks of selection bias, with summary estimates of 18% (95% CI 9–26%, I<sup>2</sup> 84%, 9 studies) [13] and 23% (95% CI 16–30%, I<sup>2</sup> 92%, 21 studies) [11]. In both reviews, with studies published up to mid-2020, many included studies used designs that we defined as contact or outbreak investigations (Fig 1, S2 Table, S2 Fig). Sah et al. reviewed studies published up to April 2021 and their subgroup estimate from studies in long-term care facilities, which include many outbreak investigations, was 17.8%, 95% CI 9.7-30.3%, 15 studies [16]. The summary estimates from all these reviews are compatible with our estimate from 46 studies in similar settings (19%, 95% CI 15-25%, prediction interval 2-70%, I<sup>2</sup> 90%) (Fig 1). It may not be possible to obtain a single summary estimate from published literature of the proportion of persistently asymptomatic SARS-CoV-2 infection. Estimates from meta-analysis might be precise, but are likely to be unreliable owing to unacceptably high levels of heterogeneity. In three large systematic reviews, overall estimates had narrow confidence intervals [14-16], but I<sup>2</sup> values were 94-99% and prediction intervals, which show the extent of all between-study variability were not reported [17]. The prediction intervals that we calculated extended more or less from zero to 100% (\$2 Appendix), making differences in estimates between these studies hard to interpret. We expected this update to our living systematic review to provide a more precise and less heterogeneous estimate of the proportion of people with asymptomatic SARS-CoV-2 than in the previous version [12]. In particular, we expected that studies that detect SARS-CoV-2 through screening of defined populations and follow up of those infected would be less affected by biases in study methodology [30] and would provide a more accurate estimate of persistently asymptomatic SARS-CoV-2, which should be influenced mainly by properties of the virus and the host response to infection [182]. Study design was the factor that explained the largest proportion of variability in this review (S2 Appendix). Information bias, resulting from the way in which asymptomatic status is determined, was the factor most strongly associated with the estimated proportion of asymptomatic infection in screening studies (Table 2). Studies based on contact and outbreak investigations might obtain more detailed data about

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

symptoms, resulting in lower estimates of the proportion that is classified as asymptomatic. Symptom report also differs between different groups of study participants, even within the same study, and could also contribute to heterogeneity [183]. Age might play a role as children appear more likely than adults to have an asymptomatic course of infection, but age was poorly reported and could not be examined in detail (Table 1, Table 2). The analysis of secondary attack rates in this update now provides strong evidence of lower infectiousness of people with asymptomatic than symptomatic infection (Fig 2). The difference in secondary attack rates between asymptomatic and symptomatic index cases in our meta-analysis is smaller and less biased than in systematic reviews that analyse groups of studies reporting asymptomatic index cases and of symptomatic cases separately [182,184]. In meta-analyses of two proportions, the direct comparison within studies reduces heterogeneity and is less biased [34]. Since SARS-CoV-2 can be transmitted a few days before the onset of symptoms [185], presymptomatic transmission likely contributes substantially to overall SARS-CoV-2 epidemics. If both the proportion and transmissibility of asymptomatic infection are relatively low, people with asymptomatic SARS-CoV-2 infection should account for a smaller proportion of overall transmission than presymptomatic individuals. This is consistent with the findings of modelling studies in our review, although the absence of descriptions of the epidemic context in many studies made it difficult to compare findings across studies. Implications and unanswered questions This living systematic review shows the challenges of synthesising evidence from observational epidemiological studies. Heterogeneity in systematic reviews of prevalence is a recognised challenge [34,186]. Methodological guidance to refrain from meta-analysis, and to report prediction intervals, when the variability between studies is extreme is often ignored in favour of summary estimates, which are easy to cite [18,20]. Part of the heterogeneity in our review arises from the fact that many studies were not designed to estimate the proportion of asymptomatic SARS-CoV-2 infection. The incomplete descriptions of inclusion criteria, response rates, follow-up and of definitions of symptom

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

status [1] made it difficult to assess the risks of bias and to investigate their contribution to betweenstudy heterogeneity. The finding that, in studies of contact and outbreak investigations, a substantial minority of people with SARS-CoV-2 infection remains asymptomatic throughout the course of infection, and that almost half of all transmission might occur before symptoms develop has already had implications for prevention. When SARS-CoV-2 community transmission levels are high, physical distancing measures and mask-wearing need to be sustained to prevent transmission from close contact with people with asymptomatic and presymptomatic infection. Integration of evidence from epidemiological, clinical and laboratory studies will help to clarify the relative infectiousness of asymptomatic SARS-CoV-2. Studies using viral culture as well as RNA detection are needed since RT-PCR defined viral loads appear to be broadly similar in asymptomatic and symptomatic people [180,187]. Determining the viral dynamics and full clinical spectrum of infection with variants of concern is important. Variants classed as omicron differ substantially from all earlier SARS-CoV-2 variants. with high infectiousness and immune evasion [188], and viral characteristics and immunity could influence the occurrence of asymptomatic infection. Studies published in early 2022 are already reporting a wide range of estimates of asymptomatic omicron infection. In India, from the date of emergence of the omicron variant, 24 November 2021 to 4 January 2022, authors reported a high proportion of asymptomatic omicron variant infections (56.7% of 291) but did not report any followup and >80% of participants had been vaccinated [189]. In contrast, authors of a cohort study of an outbreak of omicron SARS-CoV-2 in Norway, found only 1 of 81 infections in a highly vaccinated group was asymptomatic after 10 days of follow-up [190]. There are increasing challenges for studies relying on routine health service or surveillance data; in many jurisdictions, indications for routine testing are being reduced, which will make selection biases more likely, and mandated quarantine and isolation periods for people with diagnosed SARS-CoV-2 infection are being reduced, which will increase information biases in the ascertainment of persistent asymptomatic status. Researchers need to design studies to address this specific research question for each variant of concern, taking into

534

535

536

537

538

account vaccination status and prior infection. There are ongoing prospective studies that collect appropriate data [125], for which improved reporting could address the requirements for assessing asymptomatic infection status fully, but ongoing funding for these studies is not secure [191]. Without prospective longitudinal studies with methods that minimise selection and measurement biases, further updates to this living systematic review are unlikely to provide a reliable summary estimate of the proportion of asymptomatic infections caused by SARS-CoV-2.

## References

- 541 Meyerowitz EA, Richterman A, Bogoch I, Low N, Cevik M. Towards an Accurate and
- Systematic Characterisation of Persistently Asymptomatic Infection with Sars-Cov-2. Lancet Infect 542
- Dis 2021;21(6):e163-e9. Epub 2020/12/11. <a href="https://doi.org/10.1016/S1473-3099(20)30837-9">https://doi.org/10.1016/S1473-3099(20)30837-9</a> PubMed 543
- 544 PMID: 33301725; PubMed Central PMCID: 7834404.
- Day M. Covid-19: Four Fifths of Cases Are Asymptomatic, China Figures Indicate. BMJ. 545
- 2020;369:m1375. Epub 2020/04/04. https://doi.org/10.1136/bmj.m1375. PubMed PMID: 32241884. 546
- 547 Ing AJ, Cocks C, Green JP. Covid-19: In the Footsteps of Ernest Shackleton. Thorax. 3.
- 548 2020;75(8):693-4. https://doi.org/10.1136/thoraxjnl-2020-215091.
- 549 Griffith GJ, Morris TT, Tudball MJ, Herbert A, Mancano G, Pike L, et al. Collider Bias
- 550 Undermines Our Understanding of Covid-19 Disease Risk and Severity. Nature Communications.
- 2020;11(1):5749. https://doi.org/10.1038/s41467-020-19478-2. 551
- Lipsitch M, Swerdlow DL, Finelli L. Defining the Epidemiology of Covid-19 Studies 552
- Needed. N Engl J Med. 2020. Epub 2020/02/20. https://doi.org/10.1056/nejmp2002125. PubMed 553
- PMID: 32074416. 554
- 555 6. Liu Y, Morgenstern C, Kelly J, Lowe R, Jit M. The Impact of Non-Pharmaceutical
- 556 Interventions on Sars-Cov-2 Transmission across 130 Countries and Territories. BMC Med.
- 557 2021;19(1):40. Epub 20210205. https://doi.org/10.1186/s12916-020-01872-8. PubMed PMID:
- 558 33541353; PubMed Central PMCID: 7861967.
- Ferretti L, Wymant C, Kendall M, Zhao L, Nurtay A, Abeler-Dorner L, et al. Quantifying 559 7.
- Sars-Cov-2 Transmission Suggests Epidemic Control with Digital Contact Tracing, Science. 560
- 561 2020;368(6491). Epub 2020/04/03. https://doi.org/10.1126/science.abb6936. PubMed PMID:
- 562 32234805; PubMed Central PMCID: PMC7164555.
- 8. World Health Organization. Covid-19 Vaccines [Access Date: 16.03.2020]. Available from: 563
- 564 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines.
- World Health Organization. Tracking Sars-Cov-2 Variants [Access Date:16.03.2020]. 565
- Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/. 566
- Ipekci AM, Buitrago-Garcia D, Meili KW, Krauer F, Prajapati N, Thapa S, et al. Outbreaks of 567 10.
- Publications About Emerging Infectious Diseases: The Case of Sars-Cov-2 and Zika Virus. BMC 568
- Med Res Methodol. 2021;21(1):50. Epub 20210311. https://doi.org/10.1186/s12874-021-01244-7. 569
- PubMed PMID: 33706715; PubMed Central PMCID: 7948668. 570
- 571 11. Beale S, Hayward A, Shallcross L, Aldridge R, Fragaszy E. A Rapid Review and Meta-
- 572 Analysis of the Asymptomatic Proportion of Pcr-Confirmed Sars-Cov-2 Infections in Community
- Settings [Version 1; Peer Review: 1 Approved with Reservations]. Wellcome Open Research. 573
- 574 2020;5(266). https://doi.org/10.12688/wellcomeopenres.16387.1.
- 575 Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al.
- 576 Occurrence and Transmission Potential of Asymptomatic and Presymptomatic Sars-Cov-2 Infections:
- 577 A Living Systematic Review and Meta-Analysis, PLoS Med. 2020;17(9):e1003346.
- 578 https://doi.org/10.1371/journal.pmed.1003346.
- Byambasuren O, Cardona M, Bell K, Clark J, McLaws ML, Glasziou P. Estimating the 579
- 580 Extent of Asymptomatic Covid-19 and Its Potential for Community Transmission: Systematic Review

- and Meta-Analysis. Official Journal of the Association of Medical Microbiology and Infectious
- 582 Disease Canada. 2020; Volume 5(Issue 4):pp. 223-34. <a href="https://doi.org/10.3138/jammi-2020-0030">https://doi.org/10.3138/jammi-2020-0030</a>.
- 583 14. Chen X, Huang Z, Wang J, Zhao S, Wong MC-S, Chong KC, et al. Ratio of Asymptomatic
- Covid-19 Cases among Ascertained Sars-Cov-2 Infections in Different Regions and Population
- Groups in 2020: A Systematic Review and Meta-Analysis Including 130 123 Infections from 241
- 586 Studies. BMJ Open. 2021;11(12):e049752. <a href="http://dx.doi.org/10.1136/bmjopen-2021-049752">http://dx.doi.org/10.1136/bmjopen-2021-049752</a>.
- 587 15. Ma Q, Liu J, Liu Q, Kang L, Liu R, Jing W, et al. Global Percentage of Asymptomatic Sars-
- Cov-2 Infections among the Tested Population and Individuals with Confirmed Covid-19 Diagnosis:
- A Systematic Review and Meta-Analysis. JAMA Network Open. 2021;4(12):e2137257-e.
- 590 <u>https://doi.org/10.1001/jamanetworkopen.2021.37257</u>.
- 591 16. Sah P, Fitzpatrick MC, Zimmer CF, Abdollahi E, Juden-Kelly L, Moghadas SM, et al.
- 592 Asymptomatic Sars-Cov-2 Infection: A Systematic Review and Meta-Analysis. Proc Natl Acad Sci U
- 593 S A. 2021;118(34). Epub 2021/08/12. https://doi.org/10.1073/pnas.2109229118. PubMed PMID:
- 594 34376550; PubMed Central PMCID: 8403749.
- 595 17. Riley RD, Higgins JP, Deeks JJ. Interpretation of Random Effects Meta-Analyses. BMJ.
- 596 2011;342:d549. https://doi.org/10.1136/bmj.d549.
- 597 18. McKenzie JE, Brennan SE. Synthesizing and Presenting Findings Using Other Methods.
- Cochrane Handbook for Systematic Reviews of Interventions 2019. p. 321-47.
- 599 https://doi.org/10.1002/9781119536604.ch12.
- 600 19. Higgins JPT, Thompson SG, Spiegelhalter DJ. A Re-Evaluation of Random-Effects Meta-
- Analysis. J R Stat Soc Ser A Stat Soc. 2009;172(1):137-59. <a href="https://dx.doi.org/10.1111%2Fj.1467-">https://dx.doi.org/10.1111%2Fj.1467-</a>
- 602 <u>985X.2008.00552.x.</u> PubMed PMID: 19381330.
- 603 20. Deeks JJ, Higgins J, Altman D. Chapter 10: Analysing Data and Undertaking Meta-Analyses.
- 2022. Available from: https://training.cochrane.org/handbook/current/chapter-10#section-10-10-2.
- 605 21. Buitrago-Garcia D, Ipekci AM, Heron L, Imeri H, Araujo-Chaveron L, Arevalo-Rodriguez I,
- et al. Occurrence and Transmission Potential of Asymptomatic and Presymptomatic Sars-Cov-2
- 607 Infections: A Living Systematic Review and Meta-Analysis. medRxiv [Preprint].
- 608 2022:2022.01.20.22269581. https://doi.org/10.1101/2022.01.20.22269581.
- 609 22. Elliott JH, Turner T, Clavisi O, Thomas J, Higgins JP, Mavergames C, et al. Living
- Systematic Reviews: An Emerging Opportunity to Narrow the Evidence-Practice Gap. PLoS Med.
- 611 2014;11(2):e1001603. https://doi.org/10.1371/journal.pmed.1001603. PubMed PMID: 24558353;
- PubMed Central PMCID: 3928029.
- 613 23. Buitrago-Garcia D, Egli-Gany D, Counotte M, Hossmann S, Imeri H, Salanti G, et al. The
- Role of Asymptomatic Sars-Cov-2 Infections: Rapid Living Systematic Review and Meta-Analysis.
- 615 Version 1. medRxiv [Preprint]. 2020. https://doi.org/10.1101/2020.04.25.20079103
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
- Prisma 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. BMJ.
- 618 2021;372:n71. <a href="https://doi.org/10.1136/bmj.n71">https://doi.org/10.1136/bmj.n71</a>.
- 619 25. Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al. Synthesis
- without Meta-Analysis (Swim) in Systematic Reviews: Reporting Guideline. BMJ. 2020;368:16890.
- 621 <a href="https://doi.org/10.1136/bmj.16890">https://doi.org/10.1136/bmj.16890</a>.

- 622 26. Counotte M, Imeri H, Ipekci M, Low N. Covid-19 Living Evidence Bern: Institute of Social and
- Preventive Medicine, University of Bern; 2020 [Access Date; cited 2020 09.05.2020]. Covid-19
- 624 living evidence landing page]. Available from: <a href="https://ispmbern.github.io/covid-19/living-review/">https://ispmbern.github.io/covid-19/living-review/</a>.
- 625 27. Kahale L, Elkhoury R, El Mikati I, Pardo-Hernandez H, Khamis A, Sch, nemann H, et al.
- Tailored Prisma 2020 Flow Diagrams for Living Systematic Reviews: A Methodological Survey and
- a Proposal [Version 2; Peer Review: 1 Approved, 1 Approved with Reservations]. F1000Research.
- 628 2021;10(192). <a href="https://doi.org/10.12688/f1000research.51723.2">https://doi.org/10.12688/f1000research.51723.2</a>.
- 629 28. Joanna Briggs Institute. The Joanna Briggs Institute Critical Appraisal Tools for Use in Jbi
- 630 Systematic Reviews–Checklist for Case Series Adelaide2017 [Access Date:10.06.2020]. Available
- from: <a href="https://joannabriggs.org/ebp/critical\_appraisal\_tools">https://joannabriggs.org/ebp/critical\_appraisal\_tools</a>.
- Boyle MH. Guidelines for Evaluating Prevalence Studies. Evid Based Ment Health.
- 633 1998;1(2):37-40. http://ebmh.bmj.com/content/1/2/37.full.pdf.
- 634 30. Accorsi EK, Qiu X, Rumpler E, Kennedy-Shaffer L, Kahn R, Joshi K, et al. How to Detect
- and Reduce Potential Sources of Biases in Studies of Sars-Cov-2 and Covid-19. Eur J Epidemiol.
- 636 2021:179-96. Epub 2021/02/27. <a href="https://doi.org/10.1007/s10654-021-00727-7">https://doi.org/10.1007/s10654-021-00727-7</a>. PubMed PMID:
- 637 33634345; PubMed Central PMCID: 7906244.
- 538 31. Jaime Caro J, Eddy DM, Kan H, Kaltz C, Patel B, Eldessouki R, et al. Questionnaire to
- Assess Relevance and Credibility of Modeling Studies for Informing Health Care Decision Making:
- An Ispor-Amcp-Npc Good Practice Task Force Report. Value Health. 2014;17(2):174-82.
- 641 https://doi.org/10.1016/j.jval.2014.01.003. PubMed PMID: 24636375.
- 642 32. Balduzzi S, Rucker G, Schwarzer G. How to Perform a Meta-Analysis with R: A Practical
- Tutorial. Evid Based Ment Health. 2019;22(4):153-60. Epub 2019/09/30.
- 644 https://doi.org/10.1136/ebmental-2019-300117. PubMed PMID: 31563865.
- Newcombe RG. Two-Sided Confidence Intervals for the Single Proportion: Comparison of
- Seven Methods. Stat Med. 1998;17(8):857-72. https://doi.org/10.1002/(sici)1097-
- 647 0258(19980430)17:8%3C857::aid-sim777%3E3.0.co;2-e.
- 648 34. Schwarzer G, Rücker G. Meta-Analysis of Proportions. Methods Mol Biol. 2022;2345:159-
- 72. https://doi.org/10.1007/978-1-0716-1566-9\_10. PubMed PMID: 34550590.
- 25. Zhang W, Cheng W, Luo L, Ma Y, Xu C, Qin P, et al. Secondary Transmission of
- 651 Coronavirus Disease from Presymptomatic Persons, China. Emerg Infect Dis. 2020;26(8):1924-6.
- 652 Epub 2020/05/27. https://doi.org/10.3201/eid2608.201142. PubMed PMID: 32453686; PubMed
- 653 Central PMCID: 7392433.
- 4654 36. Yousaf AR, Duca LM, Chu V, Reses HE, Fajans M, Rabold EM, et al. A Prospective Cohort
- Study in Nonhospitalized Household Contacts with Severe Acute Respiratory Syndrome Coronavirus
- 2 Infection: Symptom Profiles and Symptom Change over Time. Clin Infect Dis. 2021;73(7):e1841-
- e9. Epub 2020/07/29. https://doi.org/10.1093/cid/ciaa1072. PubMed PMID: 32719874; PubMed
- 658 Central PMCID: 7454397.
- 459 37. Yau K, Muller MP, Lin M, Siddiqui N, Neskovic S, Shokar G, et al. Covid-19 Outbreak in an
- 660 Urban Hemodialysis Unit. Am J Kidney Dis. 2020;76(5):690-5 e1. Epub 2020/07/19.
- 661 https://doi.org/10.1053/j.ajkd.2020.07.001. PubMed PMID: 32681983; PubMed Central PMCID:
- 7362862.

- 463 38. Yang N, Shen Y, Shi C, Ma AHY, Zhang X, Jian X, et al. In-Flight Transmission Cluster of
- 664 Covid-19: A Retrospective Case Series. Infect Dis (Lond). 2020;52(12):891-901. Epub 2020/08/01.
- https://doi.org/10.1080/23744235.2020.1800814. PubMed PMID: 32735163.
- 39. Xie W, Chen Z, Wang Q, Song M, Cao Y, Wang L, et al. Infection and Disease Spectrum in
- Individuals with Household Exposure to Sars-Cov-2: A Family Cluster Cohort Study. J Med Virol.
- 2021;93(5):3033-46. Epub 20210212. <a href="https://doi.org/10.1002/jmv.26847">https://doi.org/10.1002/jmv.26847</a>. PubMed PMID: 33538342;
- PubMed Central PMCID: PMC8014049.
- Wu J, Huang Y, Tu C, Bi C, Chen Z, Luo L, et al. Household Transmission of Sars-Cov-2,
- 671 Zhuhai, China, 2020. Clin Infect Dis. 2020;71(16):2099-108. Epub 2020/05/12.
- 672 https://doi.org/10.1093/cid/ciaa557. PubMed PMID: 32392331; PubMed Central PMCID: 7239243.
- Wong J, Abdul Aziz ABZ, Chaw L, Mahamud A, Griffith MM, Ying-Ru LO, et al. High
- Proportion of Asymptomatic and Presymptomatic Covid-19 Infections in Travelers and Returning
- Residents to Brunei. J Travel Med. 2020. https://doi.org/10.1093/jtm/taaa066.
- 676 42. Wi YM, Lim SJ, Kim SH, Lim S, Lee SJ, Ryu BH, et al. Response System for and
- 677 Epidemiological Features of Covid-19 in Gyeongsangnam-Do Province in South Korea. Clin Infect
- Dis. 2021;72(4):661-7. Epub 2020/07/17. https://doi.org/10.1093/cid/ciaa967. PubMed PMID:
- 679 32672789; PubMed Central PMCID: 7454481.
- White EM, Santostefano CM, Feifer RA, Kosar CM, Blackman C, Gravenstein S, et al.
- 681 Asymptomatic and Presymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection
- Rates in a Multistate Sample of Skilled Nursing Facilities. JAMA Intern Med. 2020;180(12):1709-11.
- 683 Epub 2020/10/20. <a href="https://doi.org/10.1001/jamainternmed.2020.5664">https://doi.org/10.1001/jamainternmed.2020.5664</a>. PubMed PMID: 33074318;
- 684 PubMed Central PMCID: 7573793.
- 685 44. Weinbergerova B, Mayer J, Hrabovsky S, Novakova Z, Pospisil Z, Martykanova L, et al.
- 686 Covid-19's Natural Course among Ambulatory Monitored Outpatients. Sci Rep. 2021;11(1):10124.
- 687 Epub 20210512. https://doi.org/10.1038/s41598-021-89545-1. PubMed PMID: 33980931; PubMed
- 688 Central PMCID: PMC8115337.
- Wadhwa A, Fisher KA, Silver R, Koh M, Arons MM, Miller DA, et al. Identification of
- 690 Presymptomatic and Asymptomatic Cases Using Cohort-Based Testing Approaches at a Large
- 691 Correctional Facility-Chicago, Illinois, USA, May 2020. Clin Infect Dis. 2021;72(5):e128-e35. Epub
- 692 2020/12/04. <a href="https://doi.org/10.1093/cid/ciaa1802">https://doi.org/10.1093/cid/ciaa1802</a>. PubMed PMID: 33270101; PubMed Central
- 693 PMCID: 7799274.
- 694 46. Vohra LM, Jabeen D, Asif N, Ahad A. Covid-19 Pandemic and Breast Cancer Management:
- A Retrospective Observational Clinical Study from Pakistan. Ann Med Surg (Lond). 2021;63:102151.
- 696 Epub 20210204. https://doi.org/10.1016/j.amsu.2021.01.099. PubMed PMID: 33564461; PubMed
- 697 Central PMCID: PMC7860941.
- 698 47. Vinuela MC, De Leon-Luis JA, Alonso R, Catalan P, Lizarraga S, Munoz P, et al. Sars-Cov-2
- 699 Screening of Asymptomatic Women Admitted for Delivery Must Be Performed with a Combination
- of Microbiological Techniques: An Observational Study. Rev Esp Quimioter. 2020;33(6):415-21.
- 701 Epub 2020/09/19. https://doi.org/10.37201/req/088.2020. PubMed PMID: 32945157; PubMed
- 702 Central PMCID: 7712338.
- 703 48. Varnell C, Jr., Harshman LA, Smith L, Liu C, Chen S, Al-Akash S, et al. Covid-19 in
- Pediatric Kidney Transplantation: The Improving Renal Outcomes Collaborative. Am J Transplant.
- 705 2021;21(8):2740-8. Epub 2021/01/17. https://doi.org/10.1111/ajt.16501. PubMed PMID: 33452854;
- 706 PubMed Central PMCID: 8013281.

- 707 49. van den Besselaar JH, Sikkema RS, Koene F, van Buul LW, Oude Munnink BB, Frenay I, et
- al. Are Presymptomatic Sars-Cov-2 Infections in Nursing Home Residents Unrecognised
- 709 Symptomatic Infections? Sequence and Metadata from Weekly Testing in an Extensive Nursing
- 710 Home Outbreak. Age Ageing. 2021;50(5):1454-63. Epub 2021/05/09.
- 711 https://doi.org/10.1093/ageing/afab081. PubMed PMID: 33963830; PubMed Central PMCID:
- 712 8136016.
- 713 50. van Buul LW, van den Besselaar JH, Koene F, Buurman BM, Hertogh C, Group\*\* C-N-S, et
- 714 al. Asymptomatic Cases and Limited Transmission of Sars-Cov-2 in Residents and Healthcare
- Workers in Three Dutch Nursing Homes. Gerontol Geriatr Med. 2020;6:2333721420982800. Epub
- 716 2021/01/12. <a href="https://doi.org/10.1177/2333721420982800">https://doi.org/10.1177/2333721420982800</a>. PubMed PMID: 33426178; PubMed
- 717 Central PMCID: 7756037.
- 718 51. Uysal E, Kilinçer A, Cebeci H, Özer H, Demir NA, Öztürk M, et al. Chest Ct Findings in Rt-
- 719 Pcr Positive Asymptomatic Covid-19 Patients. Clinical Imaging. 2021;77:37-42.
- 720 https://doi.org/10.1016/j.clinimag.2021.01.030.
- 721 52. Uçkay I, Steinwender L, Burkhard J, Holy D, Strähl M, Farshad M. Outcomes of
- Asymptomatic Hospital Employees in Covid-19 Post-Exposure Quarantine During the Second
- 723 Pandemic Wave in Zurich. J Hosp Infect. 2021;113:189-91. Epub 20210421.
- 724 https://doi.org/10.1016/j.jhin.2021.04.010. PubMed PMID: 33891983; PubMed Central PMCID:
- 725 PMC8057933.
- 726 53. Turunen T, Kontunen K, Sugulle K, Hieta P, Snellman O, Hussein I, et al. Covid-19 Outbreak
- at a Reception Centre for Asylum Seekers in Espoo, Finland. J Migr Health. 2021;3:100043. Epub
- 728 20210416. https://doi.org/10.1016/j.jmh.2021.100043. PubMed PMID: 33880457; PubMed Central
- 729 PMCID: PMC8051004.
- 730 54. Treibel TA, Manisty C, Burton M, McKnight NA, Lambourne J, Augusto JB, et al. Covid-19:
- 731 Pcr Screening of Asymptomatic Health-Care Workers at London Hospital. Lancet. 2020.
- 732 https://doi.org/10.1016/s0140-6736(20)31100-4.
- 733 55. Tian S, Wu M, Chang Z, Wang Y, Zhou G, Zhang W, et al. Epidemiological Investigation
- and Intergenerational Clinical Characteristics of 24 Coronavirus Disease Patients Associated with a
- Supermarket Cluster: A Retrospective Study. BMC Public Health. 2021;21(1):647. Epub 2021/04/03.
- 736 <a href="https://doi.org/10.1186/s12889-021-10713-z">https://doi.org/10.1186/s12889-021-10713-z</a>. PubMed PMID: 33794836; PubMed Central PMCID:
- 737 8016429.
- 738 56. Theuring S, Thielecke M, van Loon W, Hommes F, Hulso C, von der Haar A, et al. Sars-Cov-
- 739 2 Infection and Transmission in School Settings During the Second Covid-19 Wave: A Cross-
- 740 Sectional Study, Berlin, Germany, November 2020. Euro Surveill. 2021;26(34). Epub 2021/08/28.
- 741 https://doi.org/10.2807/1560-7917.es.2021.26.34.2100184. PubMed PMID: 34448448; PubMed
- 742 Central PMCID: 8393892.
- 743 57. Taylor J, Carter RJ, Lehnertz N, Kazazian L, Sullivan M, Wang X, et al. Serial Testing for
- 744 Sars-Cov-2 and Virus Whole Genome Sequencing Inform Infection Risk at Two Skilled Nursing
- Facilities with Covid-19 Outbreaks Minnesota, April-June 2020. MMWR Morb Mortal Wkly Rep.
- 746 2020;69(37):1288-95. Epub 2020/09/24. https://doi.org/10.15585/mmwr.mm6937a3. PubMed PMID:
- 747 32966272; PubMed Central PMCID: 7498172.
- 748 58. Tanacan A, Erol SA, Turgay B, Anuk AT, Secen EI, Yegin GF, et al. The Rate of Sars-Cov-2
- 749 Positivity in Asymptomatic Pregnant Women Admitted to Hospital for Delivery: Experience of a
- 750 Pandemic Center in Turkey. Eur J Obstet Gynecol Reprod Biol. 2020;253:31-4. Epub 2020/08/09.
- 751 https://doi.org/10.1016/j.ejogrb.2020.07.051. PubMed PMID: 32763728; PubMed Central PMCID:
- 752 7390745.

- 753 59. Tan-Loh J, Cheong BMK. A Descriptive Analysis of Clinical Characteristics of Covid-19
- among Healthcare Workers in a District Specialist Hospital. Med J Malaysia. 2021;76(1):24-8. Epub
- 755 2021/01/30. <a href="https://pubmed.ncbi.nlm.nih.gov/33510104/">https://pubmed.ncbi.nlm.nih.gov/33510104/</a>. PubMed PMID: 33510104.
- 756 60. Stock AD, Bader ER, Cezayirli P, Inocencio J, Chalmers SA, Yassari R, et al. Covid-19
- 757 Infection among Healthcare Workers: Serological Findings Supporting Routine Testing. Front Med
- 758 (Lausanne). 2020;7:471. Epub 2020/09/26. https://doi.org/10.3389/fmed.2020.00471. PubMed
- 759 PMID: 32974370; PubMed Central PMCID: 7472984.
- 760 61. Starling A, White E, Showell D, Wyllie D, Kapadia S, Balakrishnan R. Whole Care Home
- Testing for Covid-19 in a Local Authority Area in the United Kingdom. medRxiv [Preprint]. 2020.
- 762 https://doi.org/10.1101/2020.08.06.20162859.
- 763 62. Smith E, Aldus CF, Brainard J, Dunham S, Hunter PR, Steel N, et al. Testing for Sars-Cov-2
- in Care Home Staff and Residents in English Care Homes: A Service Evaluation. medRxiv [Preprint].
- 765 2020. https://doi.org/10.1101/2020.08.04.20165928.
- 766 63. Shi SM, Bakaev I, Chen H, Travison TG, Berry SD. Risk Factors, Presentation, and Course of
- 767 Coronavirus Disease 2019 in a Large, Academic Long-Term Care Facility. J Am Med Dir Assoc.
- 768 2020;21(10):1378-83.e1. Epub 20200825. https://doi.org/10.1016/j.jamda.2020.08.027. PubMed
- 769 PMID: 32981664; PubMed Central PMCID: 7447263.
- 570 64. Shi Q, Hu Y, Peng B, Tang XJ, Wang W, Su K, et al. Effective Control of Sars-Cov-2
- 771 Transmission in Wanzhou, China. Nat Med. 2021;27(1):86-93. Epub 20201130.
- 772 <u>https://doi.org/10.1038/s41591-020-01178-5</u>. PubMed PMID: 33257893.
- 773 65. Schwierzeck V, Konig JC, Kuhn J, Mellmann A, Correa-Martinez CL, Omran H, et al. First
- Reported Nosocomial Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 in a Pediatric
- 775 Dialysis Unit. Clin Infect Dis. 2021;72(2):265-70. Epub 2021/01/28.
- 776 <a href="https://doi.org/10.1093/cid/ciaa491">https://doi.org/10.1093/cid/ciaa491</a>. PubMed PMID: 33501962; PubMed Central PMCID: 7197625.
- 577 66. Schmitt J, Genet E, Danguy Des Deserts M, Chauvet-Atin S, Cungi PJ, Aries P, et al. Sars
- 778 Cov2 Outbreak Management on a Landing Helicopter Dock: An Observational Retrospective Study.
- 779 Infect Dis Now. 2021;51(5):424-8. Epub 20210619. <a href="https://doi.org/10.1016/j.idnow.2021.06.303">https://doi.org/10.1016/j.idnow.2021.06.303</a>.
- 780 PubMed PMID: 34157429; PubMed Central PMCID: PMC8214318.
- 781 67. Say D, Crawford N, McNab S, Wurzel D, Steer A, Tosif S. Post-Acute Covid-19 Outcomes in
- 782 Children with Mild and Asymptomatic Disease. Lancet Child Adolesc Health. 2021;5(6):e22-e3.
- 783 Epub 20210421. https://doi.org/10.1016/s2352-4642(21)00124-3. PubMed PMID: 33891880;
- 784 PubMed Central PMCID: PMC8057863.
- 785 68. Romao VC, Oliveira-Ramos F, Cruz-Machado AR, Martins P, Barreira S, Silva-Dinis J, et al.
- A Covid-19 Outbreak in a Rheumatology Department Upon the Early Days of the Pandemic. Front
- 787 Med (Lausanne). 2020;7:576162. Epub 2020/10/27. https://doi.org/10.3389/fmed.2020.576162.
- 788 PubMed PMID: 33102507; PubMed Central PMCID: 7546334.
- 789 69. Rivett L, Sridhar S, Sparkes D, Routledge M, Jones NK, Forrest S, et al. Screening of
- 790 Healthcare Workers for Sars-Cov-2 Highlights the Role of Asymptomatic Carriage in Covid-19
- 791 Transmission. Elife. 2020;9. Epub 2020/05/12. <a href="https://doi.org/10.7554/elife.58728">https://doi.org/10.7554/elife.58728</a>. PubMed PMID:
- 792 32392129.
- 793 70. Rincón A, Moreso F, López-Herradón A, Fernández-Robres MA, Cidraque I, Nin J, et al. The
- Keys to Control a Covid-19 Outbreak in a Haemodialysis Unit. Clinical Kidney Journal.
- 795 2020;13(4):542-9. https://doi.org/10.1093/ckj/sfaa119.

- 796 71. Ren R, Zhang Y, Li Q, McGoogan JM, Feng Z, Gao GF, et al. Asymptomatic Sars-Cov-2
- 797 Infections among Persons Entering China from April 16 to October 12, 2020. Jama. 2021;325(5):489-
- 798 92. <a href="https://doi.org/10.1001/jama.2020.23942">https://doi.org/10.1001/jama.2020.23942</a>. PubMed PMID: 33528529; PubMed Central PMCID:
- 799 PMC7856538.
- 800 72. Redditt V, Wright V, Rashid M, Male R, Bogoch I. Outbreak of Sars-Cov-2 Infection at a
- 801 Large Refugee Shelter in Toronto, April 2020: A Clinical and Epidemiologic Descriptive Analysis.
- 802 CMAJ Open. 2020;8(4):E819-E24. Epub 2020/12/10. https://doi.org/10.9778/cmajo.20200165.
- 803 PubMed PMID: 33293331; PubMed Central PMCID: 7743908.
- Rauch JN, Valois E, Ponce-Rojas JC, Aralis Z, Lach RS, Zappa F, et al. Comparison of
- 805 Severe Acute Respiratory Syndrome Coronavirus 2 Screening Using Reverse Transcriptase-
- 806 Quantitative Polymerase Chain Reaction or Crispr-Based Assays in Asymptomatic College Students.
- 807 JAMA Netw Open. 2021;4(2):e2037129. Epub 2021/02/12.
- 808 <a href="https://doi.org/10.1001/jamanetworkopen.2020.37129">https://doi.org/10.1001/jamanetworkopen.2020.37129</a>. PubMed PMID: 33570576; PubMed Central
- 809 PMCID: 7879237.
- Plucinski MM, Wallace M, Uehara A, Kurbatova EV, Tobolowsky FA, Schneider ZD, et al.
- 811 Coronavirus Disease 2019 (Covid-19) in Americans Aboard the Diamond Princess Cruise Ship. Clin
- 812 Infect Dis. 2021;72(10):e448-e57. Epub 2020/08/14. https://doi.org/10.1093/cid/ciaa1180. PubMed
- 813 PMID: 32785683; PubMed Central PMCID: 7454359.
- 75. Pizarro-Sanchez MS, Avello A, Mas-Fontao S, Stock da Cunha T, Goma-Garces E, Pereira
- M, et al. Clinical Features of Asymptomatic Sars-Cov-2 Infection in Hemodialysis Patients. Kidney
- Blood Press Res. 2021;46(1):126-34. Epub 2021/01/28. <a href="https://doi.org/10.1159/000512535">https://doi.org/10.1159/000512535</a>. PubMed
- 817 PMID: 33503627; PubMed Central PMCID: 7900451.
- 818 76. Pirnay JP, Selhorst P, Cochez C, Petrillo M, Claes V, Van der Beken Y, et al. Study of a Sars-
- 819 Cov-2 Outbreak in a Belgian Military Education and Training Center in Maradi, Niger. Viruses.
- 820 2020;12(9). Epub 2020/09/02. <a href="https://doi.org/10.3390/v12090949">https://doi.org/10.3390/v12090949</a>. PubMed PMID: 32867108;
- PubMed Central PMCID: 7552053.
- Thai PQ, Rabaa MA, Luong DH, Tan DQ, Quang TD, Quach HL, et al. The First 100 Days of
- 823 Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) Control in Vietnam. Clin Infect Dis.
- 824 2021;72(9):e334-e42. Epub 2020/08/02. <a href="https://doi.org/10.1093/cid/ciaa1130">https://doi.org/10.1093/cid/ciaa1130</a>. PubMed PMID:
- 825 32738143; PubMed Central PMCID: 7454342.
- 826 78. Pavli A, Smeti P, Papadima K, Andreopoulou A, Hadjianastasiou S, Triantafillou E, et al. A
- Cluster of Covid-19 in Pilgrims to Israel. J Travel Med. 2020;27(5). Epub 2020/06/26.
- 828 <a href="https://doi.org/10.1093/jtm/taaa102">https://doi.org/10.1093/jtm/taaa102</a>. PubMed PMID: 32584403; PubMed Central PMCID: 7337872.
- 829 79. Patel MR, Kushwaha RS, Behera M, Bhadauria DS, Yachha M, Kaul A, et al. Aftermath of
- 830 Fortnightly Universal Testing for Severe Acute Respiratory Corona Virus-2 Infection in Maintenance
- 831 Hemodialysis Patients. Semin Dial. 2021;34(5):338-46. Epub 20210624.
- 832 https://doi.org/10.1111/sdi.12997. PubMed PMID: 34169574; PubMed Central PMCID:
- 833 PMC8447208.
- 834 80. Patel MC, Chaisson LH, Borgetti S, Burdsall D, Chugh RK, Hoff CR, et al. Asymptomatic
- 835 Sars-Cov-2 Infection and Covid-19 Mortality During an Outbreak Investigation in a Skilled Nursing
- 836 Facility. Clin Infect Dis. 2020;71(11):2920-6. Epub 2020/06/18. https://doi.org/10.1093/cid/ciaa763.
- 837 PubMed PMID: 32548628; PubMed Central PMCID: 7337684.
- 838 81. Park SY, Kim YM, Yi S, Lee S, Na BJ, Kim CB, et al. Coronavirus Disease Outbreak in Call
- 839 Center, South Korea. Emerg Infect Dis. 2020;26(8):1666-70. Epub 2020/04/24.

- https://doi.org/10.3201/eid2608.201274. PubMed PMID: 32324530; PubMed Central PMCID:
- 841 7392450.
- 842 82. Park JH, Jang JH, Lee K, Yoo SJ, Shin H. Covid-19 Outbreak and Presymptomatic
- Transmission in Pilgrim Travelers Who Returned to Korea from Israel. J Korean Med Sci.
- 844 2020;35(48):e424. Epub 2020/12/15. <a href="https://doi.org/10.3346/jkms.2020.35.e424">https://doi.org/10.3346/jkms.2020.35.e424</a>. PubMed PMID:
- 33316860; PubMed Central PMCID: 7735917.
- 846 83. Pamplona J, Solano R, Ramírez M, Durandez R, Mohamed F, Pardo L, et al. High Prevalence
- of Sars-Cov-2 Infection in Patients Scheduled for Digestive Endoscopy after the Peak of the First
- Wave of the Pandemic. Gastroenterol Hepatol. 2021;44(9):614-9. Epub 20210420.
- 849 https://doi.org/10.1016/j.gastrohep.2021.03.001. PubMed PMID: 33862154; PubMed Central
- 850 PMCID: PMC8056966.
- 851 84. Paleker M, Tembo YA, Davies MA, Mahomed H, Pienaar D, Madhi SA, et al. Asymptomatic
- 852 Covid-19 in South Africa Implications for the Control of Transmission. Public Health Action.
- 853 2021;11(2):58-60. <a href="https://doi.org/10.5588/pha.20.0069">https://doi.org/10.5588/pha.20.0069</a>. PubMed PMID: 34159063; PubMed Central
- 854 PMCID: PMC8202632.
- 85. Orsi A, Domnich A, Pace VD, Ricucci V, Caligiuri P, Bottiglieri L, et al. Outbreak of Sars-
- 856 Cov-2 Lineage 20i/501y.V1 in a Nursing Home Underlines the Crucial Role of Vaccination in Both
- Residents and Staff. Vaccines. 2021;9(6):591. PubMed PMID:
- 858 https://doi.org/10.3390/vaccines9060591.
- 859 86. Nunes MC, Baillie VL, Kwatra G, Bhikha S, Verwey C, Menezes C, et al. Severe Acute
- 860 Respiratory Syndrome Coronavirus 2 Infection among Healthcare Workers in South Africa: A
- Longitudinal Cohort Study. Clin Infect Dis. 2021;73(10):1896-900.
- 862 https://doi.org/10.1093/cid/ciab398. PubMed PMID: 33949670; PubMed Central PMCID:
- 863 PMC8135922.
- 864 87. Njuguna H, Wallace M, Simonson S, Tobolowsky FA, James AE, Bordelon K, et al. Serial
- 865 Laboratory Testing for Sars-Cov-2 Infection among Incarcerated and Detained Persons in a
- 866 Correctional and Detention Facility Louisiana, April-May 2020. MMWR Morb Mortal Wkly Rep.
- 867 2020;69(26):836-40. Epub 2020/07/03. <a href="https://doi.org/10.15585/mmwr.mm6926e2">https://doi.org/10.15585/mmwr.mm6926e2</a>. PubMed PMID:
- 868 32614816; PubMed Central PMCID: 7332096.
- 869 88. Morgan SC, Aigner S, Anderson C, Belda-Ferre P, De Hoff P, Marotz CA, et al. Automated,
- 870 Miniaturized, and Scalable Screening of Healthcare Workers, First Responders, and Students for Sars-
- 871 Cov-2 in San Diego County. medRxiv [Preprint]. 2021:2021.06.25.21257885.
- 872 <a href="https://doi.org/10.1101/2021.06.25.21257885">https://doi.org/10.1101/2021.06.25.21257885</a>.
- 873 89. Migisha R, Kwesiga B, Mirembe BB, Amanya G, Kabwama SN, Kadobera D, et al. Early
- 874 Cases of Sars-Cov-2 Infection in Uganda: Epidemiology and Lessons Learned from Risk-Based
- 875 Testing Approaches March-April 2020. Global Health. 2020;16(1):114. Epub 2020/11/27.
- 876 https://doi.org/10.1186/s12992-020-00643-7. PubMed PMID: 33239041; PubMed Central PMCID:
- 877 7686950.
- 878 90. Meyers KJ, Dillman B, Williams C, Jiang J, Clifford N, Miller JL, et al. Follow-up of Sars-
- 879 Cov-2 Positive Subgroup from the Asymptomatic Novel Coronavirus Infection Study. J Med Virol.
- 880 2021;93(5):2925-31. Epub 2021/01/20. https://doi.org/10.1002/jmv.26810. PubMed PMID:
- 881 33463731; PubMed Central PMCID: 8014630.
- 882 91. Marossy A, Rakowicz S, Bhan A, Noon S, Rees A, Virk M, et al. A Study of Universal
- 883 Severe Acute Respiratory Syndrome Coronavirus 2 Rna Testing among Residents and Staff in a Large

- 884 Group of Care Homes in South London. J Infect Dis. 2021;223(3):381-8. Epub 2020/09/06.
- 885 10.1093/infdis/jiaa565. PubMed PMID: 32889532; PubMed Central PMCID: PMC7499645.
- 886 92. Marcus JE, Frankel DN, Pawlak MT, Casey TM, Cybulski RJ, Jr., Enriquez E, et al. Risk
- 887 Factors Associated with Covid-19 Transmission among Us Air Force Trainees in a Congregant
- 888 Setting. JAMA Netw Open. 2021;4(2):e210202. Epub 20210201.
- https://doi.org/10.1001/jamanetworkopen.2021.0202. PubMed PMID: 33630090; PubMed Central
- 890 PMCID: PMC7907953.
- 891 93. Malhotra S, Rahi M, Das P, Chaturvedi R, Chhibber-Goel J, Anvikar A, et al.
- 892 Epidemiological Profiles and Associated Risk Factors of Sars-Cov-2 Positive Patients Based on a
- High-Throughput Testing Facility in India. Open Biol. 2021;11(6):200288. Epub 20210602.
- 894 https://doi.org/10.1098/rsob.200288. PubMed PMID: 34062097; PubMed Central PMCID:
- 895 PMC8169211.
- 896 94. Malagon-Rojas J, Gomez-Rendon C, Parra EL, Almentero J, Palma R, Lopez R, et al. Sars-
- 897 Cov-2 and Rt-Pcr in Asymptomatic Patients: Results of a Cohort of Workers at El Dorado
- 898 International Airport in Bogota, 2020. Biomedica. 2020;40(Supl. 2):166-72. Epub 2020/11/06.
- 899 <a href="https://doi.org/10.7705/biomedica.5802">https://doi.org/10.7705/biomedica.5802</a>. PubMed PMID: 33152200; PubMed Central PMCID:
- 900 7676845.
- 901 95. Maki G, Abdollah F, Dabaja A, Suleyman G. 462. Prevalence and Outcome of Asymptomatic
- Procedural Patients with Covid-19 Infection. Open Forum Infectious Diseases.
- 903 2020;7(Supplement\_1):S298-S. <a href="https://doi.org/10.1093/ofid/ofaa439.655">https://doi.org/10.1093/ofid/ofaa439.655</a>.
- 96. Mahajan NN, Kesarwani SN, Shinde SS, Nayak A, Modi DN, Mahale SD, et al. Co-Infection
- of Malaria and Dengue in Pregnant Women with Sars-Cov-2. Int J Gynaecol Obstet.
- 906 2020;151(3):459-62. Epub 2020/10/23. <a href="https://doi.org/10.1002/ijgo.13415">https://doi.org/10.1002/ijgo.13415</a>. PubMed PMID:
- 907 33090458; PubMed Central PMCID: 7611276.
- 908 97. Machado CM, Kerbauy MN, Colturato I, Arcuri LJ, dos Santos ACF, Silva FR, et al. Clinical
- 909 Characteristics and Outcomes of Covid-19 in Hsct Recipients. Blood. 2020;136:19-. Epub
- 910 2021/08/03. https://doi.org/10.1182/blood-2020-141959. PubMed PMID: PMC8330389.
- 91. Luo L, Liu D, Liao X, Wu X, Jing Q, Zheng J, et al. Contact Settings and Risk for
- 912 Transmission in 3410 Close Contacts of Patients with Covid-19 in Guangzhou, China: A Prospective
- 913 Cohort Study. Ann Intern Med. 2020;173(11):879-87. Epub 2020/08/14.
- 914 https://doi.org/10.7326/m20-2671. PubMed PMID: 32790510; PubMed Central PMCID: 7506769.
- 915 99. London V, McLaren R, Jr., Atallah F, Cepeda C, McCalla S, Fisher N, et al. The Relationship
- 916 between Status at Presentation and Outcomes among Pregnant Women with Covid-19. Am J
- 917 Perinatol. 2020;37(10):991-4. Epub 2020/05/20. https://doi.org/10.1055/s-0040-1712164. PubMed
- 918 PMID: 32428964; PubMed Central PMCID: 7416203.
- 919 100. Lombardi A, Consonni D, Carugno M, Bozzi G, Mangioni D, Muscatello A, et al.
- 920 Characteristics of 1573 Healthcare Workers Who Underwent Nasopharyngeal Swab Testing for Sars-
- 921 Cov-2 in Milan, Lombardy, Italy. Clin Microbiol Infect. 2020;26(10):1413 e9- e13. Epub 2020/06/23.
- 922 https://doi.org/10.1016/j.cmi.2020.06.013. PubMed PMID: 32569835; PubMed Central PMCID:
- 923 7305713.
- 924 101. Letizia AG, Ramos I, Obla A, Goforth C, Weir DL, Ge Y, et al. Sars-Cov-2 Transmission
- 925 among Marine Recruits During Ouarantine. N Engl J Med. 2020;383(25):2407-16. Epub 2020/11/12.
- 926 https://doi.org/10.1056/nejmoa2029717. PubMed PMID: 33176093; PubMed Central PMCID:
- 927 PMC7675690.

- 928 102. Lee JY, Hong SW, Hyun M, Park JS, Lee JH, Suh YS, et al. Epidemiological and Clinical
- 929 Characteristics of Coronavirus Disease 2019 in Daegu, South Korea. Int J Infect Dis. 2020;98:462-6.
- 930 Epub 2020/07/24. https://doi.org/10.1016/j.ijid.2020.07.017. PubMed PMID: 32702415; PubMed
- 931 Central PMCID: 7371586.
- 932 103. Laws RL, Biraro S, Kirungi W, Gianetti B, Aibo D, Awor AC, et al. Coronavirus Disease
- 933 2019 (Covid-19) Mitigation Efforts and Testing During an in-Person Training Event-Uganda, 12-29
- 934 October 2020. Clin Infect Dis. 2021;73(Suppl 1):S42-s4. <a href="https://doi.org/10.1093/cid/ciab331">https://doi.org/10.1093/cid/ciab331</a>.
- PubMed PMID: 33912911; PubMed Central PMCID: PMC8135603.
- 936 104. Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, et al.
- 937 Suppression of a Sars-Cov-2 Outbreak in the Italian Municipality of Vo'. Nature.
- 938 2020;584(7821):425-9. Epub 2020/07/01. <a href="https://doi.org/10.1038/s41586-020-2488-1">https://doi.org/10.1038/s41586-020-2488-1</a>. PubMed
- 939 PMID: 32604404.
- 940 105. Lalani T, Lee TK, Laing ED, Ritter A, Cooper E, Lee M, et al. Sars-Cov-2 Infections and
- 941 Serologic Responses among Military Personnel Deployed on the Usns Comfort to New York City
- During the Covid-19 Pandemic. Open Forum Infect Dis. 2021;8(2):ofaa654. Epub 20210123.
- 943 <a href="https://doi.org/10.1093/ofid/ofaa654">https://doi.org/10.1093/ofid/ofaa654</a>. PubMed PMID: 33553482; PubMed Central PMCID:
- 944 PMC7856331.
- 945 106. Ladhani SN, Jeffery-Smith A, Patel M, Janarthanan R, Fok J, Crawley-Boevey E, et al. High
- 946 Prevalence of Sars-Cov-2 Antibodies in Care Homes Affected by Covid-19: Prospective Cohort
- 947 Study, England. EClinicalMedicine. 2020;28:100597. Epub 2020/11/12.
- 948 <a href="https://doi.org/10.1016/j.eclinm.2020.100597">https://doi.org/10.1016/j.eclinm.2020.100597</a>. PubMed PMID: 33173854; PubMed Central PMCID:
- 949 7644437.
- 950 107. Kutsuna S, Suzuki T, Hayakawa K, Tsuzuki S, Asai Y, Suzuki T, et al. Sars-Cov-2 Screening
- 951 Test for Japanese Returnees from Wuhan, China, January 2020. Open Forum Infect Dis.
- 952 2020;7(7):ofaa243. Epub 2020/08/06. <a href="https://doi.org/10.1093/ofid/ofaa243">https://doi.org/10.1093/ofid/ofaa243</a>. PubMed PMID:
- 953 32754627; PubMed Central PMCID: 7337761.
- 954 108. Kittang BR, Hofacker SV, Solheim SP, Kruger K, Loland KK, Jansen K. Outbreak of Covid-
- 955 19 at Three Nursing Homes in Bergen. Tidsskr Nor Laegeforen. 2020;140(11). Epub 2020/08/21.
- 956 <a href="https://doi.org/10.4045/tidsskr.20.0405">https://doi.org/10.4045/tidsskr.20.0405</a>. PubMed PMID: 32815356.
- 957 109. Kirshblum SC, DeLauter G, Lopreiato MC, Pomeranz B, Dawson A, Hammerman S, et al.
- 958 Screening Testing for Sars-Cov-2 Upon Admission to Rehabilitation Hospitals in a High Covid-19
- 959 Prevalence Community. PM R. 2020;12(10):1009-14. Epub 2020/07/24.
- 960 <a href="https://doi.org/10.1002/pmrj.12454">https://doi.org/10.1002/pmrj.12454</a>. PubMed PMID: 32700434; PubMed Central PMCID: 7404891.
- 961 110. Khondaker T, Qader MA, Gosh K, Chowdhury GN, Ferdous T, Afroz S, et al. Clinical Profile
- and Outcome of Covid -19 in Children with Pre-Existing Renal Disease. J pediatric nephrol.
- 963 2020;9(1):1-6. <a href="https://doi.org/10.22037/jpn.v9i1.33008">https://doi.org/10.22037/jpn.v9i1.33008</a>.
- 964 111. Kennelly SP, Dyer AH, Noonan C, Martin R, Kennelly SM, Martin A, et al. Asymptomatic
- 965 Carriage Rates and Case Fatality of Sars-Cov-2 Infection in Residents and Staff in Irish Nursing
- 966 Homes. Age Ageing. 2021;50(1):49-54. Epub 2020/09/29. https://doi.org/10.1093/ageing/afaa220.
- 967 PubMed PMID: 32986806; PubMed Central PMCID: 7543256.
- 968 112. Kasper MR, Geibe JR, Sears CL, Riegodedios AJ, Luse T, Von Thun AM, et al. An Outbreak
- 969 of Covid-19 on an Aircraft Carrier. N Engl J Med. 2020;383(25):2417-26. Epub 2020/11/12.
- 970 https://doi.org/10.1056/nejmoa2019375. PubMed PMID: 33176077; PubMed Central PMCID:
- 971 7675688.

- 972 113. Jones A, Fialkowski V, Prinzing L, Trites J, Kelso P, Levine M. Assessment of Day-7
- 973 Postexposure Testing of Asymptomatic Contacts of Covid-19 Patients to Evaluate Early Release from
- 974 Quarantine Vermont, May-November 2020. MMWR Morb Mortal Wkly Rep. 2021;70(1):12-3.
- 975 Epub 2021/01/08. http://dx.doi.org/10.15585/mmwr.mm7001a3. PubMed PMID: 33411700; PubMed
- 976 Central PMCID: 7790157.
- 977 114. Jeffery-Smith A, Dun-Campbell K, Janarthanan R, Fok J, Crawley-Boevey E, Vusirikala A,
- 978 et al. Infection and Transmission of Sars-Cov-2 in London Care Homes Reporting No Cases or
- 979 Outbreaks of Covid-19: Prospective Observational Cohort Study, England 2020. Lancet Reg Health
- 980 Eur. 2021;3:100038. Epub 20210122. <a href="https://doi.org/10.1016/j.lanepe.2021.100038">https://doi.org/10.1016/j.lanepe.2021.100038</a>. PubMed PMID:
- 981 33870248; PubMed Central PMCID: PMC7826003.
- 982 115. Isoldi S, Mallardo S, Marcellino A, Bloise S, Dilillo A, Iorfida D, et al. The Comprehensive
- 983 Clinic, Laboratory, and Instrumental Evaluation of Children with Covid-19: A 6-Months Prospective
- 984 Study. J Med Virol. 2021;93(5):3122-32. Epub 20210216. <a href="https://doi.org/10.1002/jmv.26871">https://doi.org/10.1002/jmv.26871</a>.
- PubMed PMID: 33570199; PubMed Central PMCID: PMC8014060.
- 986 116. Hwang CE, Kussman A, Christle JW, Froelicher V, Wheeler MT, Moneghetti KJ. Findings
- 987 from Cardiovascular Evaluation of National Collegiate Athletic Association Division I Collegiate
- 988 Student-Athletes after Asymptomatic or Mildly Symptomatic Sars-Cov-2 Infection. Clin J Sport Med.
- 989 2022;32(2):103-7. https://doi.org/10.1097/jsm.000000000000954. PubMed PMID: 34173780.
- 990 117. Hussain A, Satti L, Hanif F, Shoaib M, Ghauri MA, Khan Niazi GA, et al. Clinical and
- 991 Virological Course of Sars-Cov 2 Infected Patients in a Tertiary Care Hospital in Pakistan. J Ayub
- 992 Med Coll Abbottabad. 2020;32(Suppl 1)(4):S602-s6. <a href="https://pubmed.ncbi.nlm.nih.gov/33754515/">https://pubmed.ncbi.nlm.nih.gov/33754515/</a>.
- 993 PubMed PMID: 33754515; PubMed Central PMCID: 33754515.
- 994 118. Hurst JH, Heston SM, Chambers HN, Cunningham HM, Price MJ, Suarez L, et al. Severe
- 995 Acute Respiratory Syndrome Coronavirus 2 Infections among Children in the Biospecimens from
- 996 Respiratory Virus-Exposed Kids (Brave Kids) Study. Clinical Infectious Diseases. 2021;73(9):e2875-
- 997 e82. https://doi.org/10.1093/cid/ciaa1693.
- 998 119. Hogan CA, Gombar S, Wang H, Roltgen K, Shi RZ, Holubar M, et al. Large-Scale Testing of
- 999 Asymptomatic Healthcare Personnel for Severe Acute Respiratory Syndrome Coronavirus 2. Emerg
- 1000 Infect Dis. 2021;27(1). Epub 2020/12/02. https://doi.org/10.3201/eid2701.203892. PubMed PMID:
- 1001 33256889; PubMed Central PMCID: PMC7774535.
- 1002 120. Hoehl S, Rabenau H, Berger A, Kortenbusch M, Cinatl J, Bojkova D, et al. Evidence of Sars-
- 1003 Cov-2 Infection in Returning Travelers from Wuhan, China. N Engl J Med. 2020;382(13):1278-80.
- Epub 2020/02/19. <a href="https://doi.org/10.1056/nejmc2001899">https://doi.org/10.1056/nejmc2001899</a>. PubMed PMID: 32069388; PubMed
- 1005 Central PMCID: 7121749.
- 1006 121. Hijnen D, Marzano AV, Eyerich K, GeurtsvanKessel C, Gimenez-Arnau AM, Joly P, et al.
- 1007 Sars-Cov-2 Transmission from Presymptomatic Meeting Attendee, Germany. Emerg Infect Dis.
- 1008 2020;26(8):1935-7. Epub 2020/05/12. <a href="https://doi.org/10.3201/eid2608.201235">https://doi.org/10.3201/eid2608.201235</a>. PubMed PMID:
- 1009 32392125; PubMed Central PMCID: 7392453.
- 1010 122. Hcini N, Maamri F, Picone O, Carod JF, Lambert V, Mathieu M, et al. Maternal, Fetal and
- 1011 Neonatal Outcomes of Large Series of Sars-Cov-2 Positive Pregnancies in Peripartum Period: A
- 1012 Single-Center Prospective Comparative Study. Eur J Obstet Gynecol Reprod Biol. 2021;257:11-8.
- 1013 Epub 2020/12/15. https://doi.org/10.1016/j.ejogrb.2020.11.068. PubMed PMID: 33310656; PubMed
- 1014 Central PMCID: 7705341.
- 1015 123. Harada S, Uno S, Ando T, Iida M, Takano Y, Ishibashi Y, et al. Control of a Nosocomial
- Outbreak of Covid-19 in a University Hospital. Open Forum Infect Dis. 2020;7(12):ofaa512. Epub

- 1017 2020/12/18. https://doi.org/10.1093/ofid/ofaa512. PubMed PMID: 33330740; PubMed Central
- 1018 PMCID: 7665726.
- 1019 124. Han X, Wei X, Alwalid O, Cao Y, Li Y, Wang L, et al. Severe Acute Respiratory Syndrome
- 1020 Coronavirus 2 among Asymptomatic Workers Screened for Work Resumption, China. Emerg Infect
- 1021 Dis. 2020;26(9). Epub 2020/06/20. <a href="https://doi.org/10.3201/eid2609.201848">https://doi.org/10.3201/eid2609.201848</a>. PubMed PMID:
- 1022 32553070; PubMed Central PMCID: 7454110.
- 1023 125. Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, et al. Sars-Cov-2 Infection
- Rates of Antibody-Positive Compared with Antibody-Negative Health-Care Workers in England: A
- Large, Multicentre, Prospective Cohort Study (Siren). Lancet. 2021;397(10283):1459-69. Epub
- 1026 20210409. <a href="https://doi.org/10.1016/s0140-6736(21)00675-9">https://doi.org/10.1016/s0140-6736(21)00675-9</a>. PubMed PMID: 33844963; PubMed
- 1027 Central PMCID: PMC8040523.
- 1028 126. Haidar G, Ayres A, King WC, McDonald M, Wells A, Mitchell SL, et al. Preprocedural Sars-
- 1029 Cov-2 Testing to Sustain Medically Needed Health Care Delivery During the Covid-19 Pandemic: A
- Prospective Observational Study. Open Forum Infectious Diseases. 2021;8(2).
- 1031 https://doi.org/10.1093/ofid/ofab022.
- 1032 127. Grijalva CG, Rolfes MA, Zhu Y, McLean HQ, Hanson KE, Belongia EA, et al. Transmission
- of Sars-Cov-2 Infections in Households Tennessee and Wisconsin, April-September 2020. MMWR
- 1034 Morb Mortal Wkly Rep. 2020;69(44):1631-4. Epub 2020/11/06.
- 1035 http://dx.doi.org/10.15585/mmwr.mm6944e1. PubMed PMID: 33151916; PubMed Central PMCID:
- 1036 7643897.
- 1037 128. Green R, Tulloch JSP, Tunnah C, Coffey E, Lawrenson K, Fox A, et al. Covid-19 Testing in
- Outbreak-Free Care Homes: What Are the Public Health Benefits? J Hosp Infect. 2021;111:89-95.
- Epub 2021/01/17. <a href="https://doi.org/10.1016/j.jhin.2020.12.024">https://doi.org/10.1016/j.jhin.2020.12.024</a>. PubMed PMID: 33453349; PubMed
- 1040 Central PMCID: 7837210.
- 1041 129. Graham NSN, Junghans C, Downes R, Sendall C, Lai H, McKirdy A, et al. Sars-Cov-2
- 1042 Infection, Clinical Features and Outcome of Covid-19 in United Kingdom Nursing Homes. J Infect.
- 1043 2020;81(3):411-9. Epub 2020/06/07. https://doi.org/10.1016/j.jinf.2020.05.073. PubMed PMID:
- 1044 32504743; PubMed Central PMCID: 7836316.
- 1045 130. Ghinai I, Davis ES, Mayer S, Toews KA, Huggett TD, Snow-Hill N, et al. Risk Factors for
- 1046 Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Homeless Shelters in Chicago,
- 1047 Illinois-March-May, 2020. Open Forum Infect Dis. 2020;7(11):ofaa477. Epub 2020/12/03.
- 1048 <a href="https://doi.org/10.1093/ofid/ofaa477">https://doi.org/10.1093/ofid/ofaa477</a>. PubMed PMID: 33263069; PubMed Central PMCID: 7665740.
- 1049 131. Gettings JR, Gold JAW, Kimball A, Forsberg K, Scott C, Uehara A, et al. Severe Acute
- 1050 Respiratory Syndrome Coronavirus 2 Transmission in a Georgia School District-United States,
- 1051 December 2020-January 2021. Clin Infect Dis. 2022;74(2):319-26.
- https://doi.org/10.1093/cid/ciab332. PubMed PMID: 33864375; PubMed Central PMCID:
- 1053 PMC8083290.
- 1054 132. Garibaldi PMM, Ferreira NN, Moraes GR, Moura JC, Espósito DLA, Volpe GJ, et al.
- 1055 Efficacy of Covid-19 Outbreak Management in a Skilled Nursing Facility Based on Serial Testing for
- 1056 Early Detection and Control. Braz J Infect Dis. 2021;25(2):101570. Epub 20210323.
- 1057 https://doi.org/10.1016/j.bjid.2021.101570. PubMed PMID: 33773990; PubMed Central PMCID:
- 1058 PMC7985963.
- 1059 133. Fisher MJ, Psevdos G. Asymptomatic Sars-Cov-2 Infection Following First Dose Mrna-1273
- 1060 Covid-19 Vaccine in a Veterans Affairs Long Term Care Facility. Am J Infect Control.

- 1061 2021;49(9):1210-1. Epub 20210625. https://doi.org/10.1016/j.ajic.2021.06.010. PubMed PMID:
- 1062 34175364; PubMed Central PMCID: PMC8225993.
- 1063 134. Ferreira VH, Chruscinski A, Kulasingam V, Pugh TJ, Dus T, Wouters B, et al. Prospective
- 1064 Observational Study and Serosurvey of Sars-Cov-2 Infection in Asymptomatic Healthcare Workers at
- a Canadian Tertiary Care Center. PLoS One. 2021;16(2):e0247258. Epub 2021/02/17.
- https://doi.org/10.1371/journal.pone.0247258. PubMed PMID: 33592074; PubMed Central PMCID:
- 1067 7886177.
- 1068 135. Fakhim H, Nasri E, Aboutalebian S, Gholipour S, Nikaeen M, Vaezi A, et al. Asymptomatic
- 1069 Carriers of Coronavirus Disease 2019 among Healthcare Workers in Isfahan, Iran. Future Virology.
- 1070 2021;16(2):93-8. https://dx.doi.org/10.2217%2Ffvl-2020-0224.
- 1071 136. Eythorsson E, Helgason D, Ingvarsson RF, Bjornsson HK, Olafsdottir LB, Bjarnadottir V, et
- al. Clinical Spectrum of Coronavirus Disease 2019 in Iceland: Population Based Cohort Study. BMJ.
- 1073 2020;371:m4529. Epub 2020/12/04. https://doi.org/10.1136/bmj.m4529. PubMed PMID: 33268329;
- 1074 PubMed Central PMCID: 7708618.
- 1075 137. Esteban I, Bergero G, Alves C, Bronstein M, Ziegler V, Wood C, et al. Asymptomatic Covid-
- 1076 19 in the Elderly: Dementia and Viral Clearance as Risk Factors for Disease Progression. TP92
- 1077 TP092 CLINICAL ADVANCES IN SARS-COV-2 AND COVID-19. 2021:A3826-A.
- https://doi.org/10.1164/ajrccm-conference.2021.203.1\_MeetingAbstracts.A3826.
- 1079 138. Edelstein M, Obi C, Chand M, Hopkins S, Brown K, Ramsay M. Sars-Cov-2 Infection in
- 1080 London, England: Changes to Community Point Prevalence around Lockdown Time, March-May
- 2020. J Epidemiol Community Health. 2021;75(2):185-8. Epub 2020/10/03.
- 1082 <a href="https://doi.org/10.1136/jech-2020-214730">https://doi.org/10.1136/jech-2020-214730</a>. PubMed PMID: 33004659; PubMed Central PMCID:
- 1083 7815898.
- 1084 139. Dora AV, Winnett A, Jatt LP, Davar K, Watanabe M, Sohn L, et al. Universal and Serial
- 1085 Laboratory Testing for Sars-Cov-2 at a Long-Term Care Skilled Nursing Facility for Veterans Los
- 1086 Angeles, California, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(21):651-5. Epub 2020/05/29.
- 1087 https://doi.org/10.15585/mmwr.mm6921e1. PubMed PMID: 32463809; PubMed Central PMCID:
- 1088 7269604.
- 1089 140. Danis K, Epaulard O, Benet T, Gaymard A, Campoy S, Bothelo-Nevers E, et al. Cluster of
- 1090 Coronavirus Disease 2019 (Covid-19) in the French Alps, 2020. Clin Infect Dis. 2020. Epub
- 1091 2020/04/12. https://doi.org/10.1093/cid/ciaa424. PubMed PMID: 32277759; PubMed Central
- 1092 PMCID: 7184384.
- 1093 141. Corcorran MA, Olin S, Rani G, Nasenbeny K, Constantino-Shor C, Holmes C, et al.
- 1094 Prolonged Persistence of Pcr-Detectable Virus During an Outbreak of Sars-Cov-2 in an Inpatient
- 1095 Geriatric Psychiatry Unit in King County, Washington. Am J Infect Control. 2021;49(3):293-8. Epub
- 1096 2020/08/23. https://doi.org/10.1016/j.ajic.2020.08.025. PubMed PMID: 32827597; PubMed Central
- 1097 PMCID: 7438365.
- 1098 142. Cheng HY, Jian SW, Liu DP, Ng TC, Huang WT, Lin HH, et al. Contact Tracing Assessment
- of Covid-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods before and
- after Symptom Onset. JAMA Intern Med. 2020;180(9):1156-63. Epub 2020/05/02.
- 1101 https://doi.org/10.1001/jamainternmed.2020.2020. PubMed PMID: 32356867; PubMed Central
- 1102 PMCID: 7195694.
- 1103 143. Chang L, Zhao L, Gong H, Wang L, Wang L. Severe Acute Respiratory Syndrome
- 1104 Coronavirus 2 Rna Detected in Blood Donations. Emerg Infect Dis. 2020;26(7):1631-3. Epub

- 1105 2020/04/04. https://doi.org/10.3201/eid2607.200839. PubMed PMID: 32243255; PubMed Central
- 1106 PMCID: 7323524.
- Chamie G, Marquez C, Crawford E, Peng J, Petersen M, Schwab D, et al. Community 1107 144.
- Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Disproportionately Affects the 1108
- Latinx Population During Shelter-in-Place in San Francisco. Clin Infect Dis. 2021;73(Suppl 2):S127-1109
- 1110 S35. Epub 2020/08/22. https://doi.org/10.1093/cid/ciaa1234. PubMed PMID: 32821935; PubMed
- Central PMCID: 7499499. 1111
- 1112 145. Cariani L, Orena BS, Ambrogi F, Gambazza S, Maraschini A, Dodaro A, et al. Time Length
- of Negativization and Cycle Threshold Values in 182 Healthcare Workers with Covid-19 in Milan, 1113
- 1114 Italy: An Observational Cohort Study. Int J Environ Res Public Health. 2020;17(15). Epub
- 1115 2020/07/29. https://doi.org/10.3390/ijerph17155313. PubMed PMID: 32718008; PubMed Central
- 1116 PMCID: 7432921.
- Cardillo L, de Martinis C, Viscardi M, Esposito C, Sannino E, Lucibelli G, et al. Sars-Cov-2 1117
- 1118 Quantitative Real Time Pcr and Viral Loads Analysis among Asymptomatic and Symptomatic
- Patients: An Observational Study on an Outbreak in Two Nursing Facilities in Campania Region 1119
- (Southern Italy). Infect Agent Cancer. 2021;16(1):45. Epub 20210622. 1120
- https://doi.org/10.1186/s13027-021-00388-x. PubMed PMID: 34158108; PubMed Central PMCID: 1121
- 1122 PMC8218569.
- 1123 147. Cao S, Gan Y, Wang C, Bachmann M, Wei S, Gong J, et al. Post-Lockdown Sars-Cov-2
- 1124 Nucleic Acid Screening in Nearly Ten Million Residents of Wuhan, China. Nat Commun.
- 1125 2020;11(1):5917. Epub 2020/11/22. https://doi.org/10.1038/s41467-020-19802-w. PubMed PMID:
- 1126 33219229; PubMed Central PMCID: 7679396.
- 1127 148. Brandstetter S, Roth S, Harner S, Buntrock-Dopke H, Toncheva AA, Borchers N, et al.
- 1128 Symptoms and Immunoglobulin Development in Hospital Staff Exposed to a Sars-Cov-2 Outbreak.
- 1129 Pediatr Allergy Immunol. 2020;31(7):841-7. Epub 2020/05/16. https://doi.org/10.1111/pai.13278.
- 1130 PubMed PMID: 32413201.
- 1131 149. Bohmer MM, Buchholz U, Corman VM, Hoch M, Katz K, Marosevic DV, et al. Investigation
- 1132 of a Covid-19 Outbreak in Germany Resulting from a Single Travel-Associated Primary Case: A Case
- 1133 Series. Lancet Infect Dis. 2020;20(8):920-8. Epub 2020/05/19. https://doi.org/10.1016/s1473-
- 3099(20)30314-5. PubMed PMID: 32422201; PubMed Central PMCID: 7228725. 1134
- Bogani G, Ditto A, Bosio S, Brusadelli C, Raspagliesi F. Cancer Patients Affected by Covid-1135 150.
- 19: Experience from Milan, Lombardy. Gynecol Oncol. 2020;158(2):262-5. Epub 2020/06/15. 1136
- 1137 https://doi.org/10.1016/j.ygyno.2020.06.161. PubMed PMID: 32534808; PubMed Central PMCID:
- 1138 7286266.
- Blain H, Gamon L, Tuaillon E, Pisoni A, Giacosa N, Albrand M, et al. Atypical Symptoms, 1139
- 1140 Sars-Cov-2 Test Results and Immunisation Rates in 456 Residents from Eight Nursing Homes Facing
- 1141 a Covid-19 Outbreak. Age Ageing. 2021;50(3):641-8. https://doi.org/10.1093/ageing/afab050.
- 1142 PubMed PMID: 33620381; PubMed Central PMCID: PMC7929417.
- 1143 Berghoff AS, Gansterer M, Bathke AC, Trutschnig W, Hungerlander P, Berger JM, et al.
- 1144 Sars-Cov-2 Testing in Patients with Cancer Treated at a Tertiary Care Hospital During the Covid-19
- 1145 Pandemic. J Clin Oncol. 2020;38(30):3547-54. Epub 2020/08/17.
- 1146 https://doi.org/10.1200/jco.20.01442. PubMed PMID: 32795227; PubMed Central PMCID: 7571795.
- Bender WR, Hirshberg A, Coutifaris P, Acker AL, Srinivas SK. Universal Testing for Severe 1147
- 1148 Acute Respiratory Syndrome Coronavirus 2 in 2 Philadelphia Hospitals: Carrier Prevalence and
- 1149 Symptom Development over 2 Weeks. Am J Obstet Gynecol MFM. 2020;2(4):100226. Epub

- 1150 2020/09/22, https://doi.org/10.1016/j.ajogmf.2020.100226. PubMed PMID: 32954248; PubMed
- 1151 Central PMCID: 7485442.
- 154. Beiting KJ, Huisingh-Scheetz M, Walker J, Graupner J, Martinchek M, Thompson K, et al.
- 1153 Management and Outcomes of a Covid-19 Outbreak in a Nursing Home with Predominantly Black
- 1154 Residents. J Am Geriatr Soc. 2021;69(5):1155-65. Epub 20210324.
- 1155 https://doi.org/10.1111/jgs.17126. PubMed PMID: 33739444; PubMed Central PMCID:
- 1156 PMC8218575.
- 1157 155. Balestrini S, Koepp MJ, Gandhi S, Rickman HM, Shin GY, Houlihan CF, et al. Clinical
- Outcomes of Covid-19 in Long-Term Care Facilities for People with Epilepsy. Epilepsy Behav.
- 2021;115:107602. Epub 2020/12/07. https://doi.org/10.1016/j.yebeh.2020.107602. PubMed PMID:
- 1160 33279440; PubMed Central PMCID: 7643621.
- 1161 156. Aslam A, Singh J, Robilotti E, Chow K, Bist T, Reidy-Lagunes D, et al. Severe Acute
- 1162 Respiratory Syndrome Coronavirus 2 Surveillance and Exposure in the Perioperative Setting with
- Universal Testing and Personal Protective Equipment Policies. Clin Infect Dis. 2021;73(9):e3013-e8.
- 1164 Epub 2020/10/23. https://doi.org/10.1093/cid/ciaa1607. PubMed PMID: 33090210; PubMed Central
- 1165 PMCID: 7665395.
- 1166 157. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic
- Sars-Cov-2 Infections and Transmission in a Skilled Nursing Facility. N Engl J Med.
- 2020;382(22):2081-90. Epub 2020/04/25. https://doi.org/10.1056/NEJMoa2008457. PubMed PMID:
- 1169 32329971; PubMed Central PMCID: 7200056.
- 1170 158. Andrikopoulou M, Madden N, Wen T, Aubey JJ, Aziz A, Baptiste CD, et al. Symptoms and
- 1171 Critical Illness among Obstetric Patients with Coronavirus Disease 2019 (Covid-19) Infection. Obstet
- 1172 Gynecol. 2020;136(2):291-9. Epub 2020/05/28. <a href="https://doi.org/10.1097/aog.00000000000003996">https://doi.org/10.1097/aog.000000000000003996</a>.
- 1173 PubMed PMID: 32459701.
- 1174 159. Alshahrani MS, Alnimr A, Alnassri S, Alfarag S, Aljehani Y, Alabdali M. Prevalence of the
- 1175 Sars-Cov-2 Infection among Post-Quarantine Healthcare Workers. J Multidiscip Healthc.
- 2020;13:1927-36. Epub 2020/12/29. <a href="https://doi.org/10.2147/jmdh.s279469">https://doi.org/10.2147/jmdh.s279469</a>. PubMed PMID:
- 1177 33363380; PubMed Central PMCID: 7752650.
- 1178 160. Almazeedi S, Al-Youha S, Jamal MH, Al-Haddad M, Al-Muhaini A, Al-Ghimlas F, et al.
- 1179 Characteristics, Risk Factors and Outcomes among the First Consecutive 1096 Patients Diagnosed
- 1180 with Covid-19 in Kuwait. EClinical Medicine. 2020;24:100448. Epub 2020/08/09.
- 1181 <a href="https://doi.org/10.1016/j.eclinm.2020.100448">https://doi.org/10.1016/j.eclinm.2020.100448</a>. PubMed PMID: 32766546; PubMed Central PMCID:
- 1182 7335246.
- 1183 161. Al-Qahtani M, AlAli S, AbdulRahman A, Salman Alsayyad A, Otoom S, Atkin SL. The
- 1184 Prevalence of Asymptomatic and Symptomatic Covid-19 in a Cohort of Quarantined Subjects. Int J
- Infect Dis. 2021;102:285-8. Epub 2020/11/07. <a href="https://doi.org/10.1016/j.ijid.2020.10.091">https://doi.org/10.1016/j.ijid.2020.10.091</a>. PubMed
- 1186 PMID: 33157290; PubMed Central PMCID: 7607262.
- 1187 162. Adhikari EH, Moreno W, Zofkie AC, MacDonald L, McIntire DD, Collins RRJ, et al.
- 1188 Pregnancy Outcomes among Women with and without Severe Acute Respiratory Syndrome
- 1189 Coronavirus 2 Infection. JAMA Netw Open. 2020;3(11):e2029256. Epub 2020/11/20.
- 1190 https://doi.org/10.1001/jamanetworkopen.2020.29256. PubMed PMID: 33211113; PubMed Central
- 1191 PMCID: 7677755.
- 1192 163. Abraha HE, Gessesse Z, Gebrecherkos T, Kebede Y, Weldegiargis AW, Tequare MH, et al.
- 1193 Clinical Features and Risk Factors Associated with Morbidity and Mortality among Patients with
- 1194 Covid-19 in Northern Ethiopia. Int J Infect Dis. 2021;105:776-83. Epub 20210316.

- https://doi.org/10.1016/j.ijid.2021.03.037. PubMed PMID: 33741488; PubMed Central PMCID: 1195
- 1196 PMC7962557.
- 1197 AbdulRahman A, AlAli S, Yaghi O, Shabaan M, Otoom S, Atkin SL, et al. Covid-19 and 164.
- Sickle Cell Disease in Bahrain. Int J Infect Dis. 2020;101:14-6. Epub 2020/09/28. 1198
- 1199 https://doi.org/10.1016/j.ijid.2020.09.1433. PubMed PMID: 32980556; PubMed Central PMCID:
- 1200 7833176.
- 1201 Wu P, Liu F, Chang Z, Lin Y, Ren M, Zheng C, et al. Assessing Asymptomatic, 165.
- 1202 Presymptomatic, and Symptomatic Transmission Risk of Severe Acute Respiratory Syndrome
- Coronavirus 2. Clin Infect Dis. 2021;73(6):e1314-e20. https://doi.org/10.1093/cid/ciab271. PubMed 1203
- 1204 PMID: 33772573; PubMed Central PMCID: PMC8083716.
- 1205 Luo L, Liu D, Liao X-l, Wu X-b, Jing Q-l, Zheng J-z, et al. Modes of Contact and Risk of
- 1206 Transmission in Covid-19 among Close Contacts. bioRxiv [Preprint]. 2020.
- https://doi.org/10.1101/2020.03.24.20042606. 1207
- 1208 Chaw L, Koh WC, Jamaludin SA, Naing L, Alikhan MF, Wong J. Analysis of Sars-Cov-2
- 1209 Transmission in Different Settings, Brunei. Emerg Infect Dis. 2020;26(11):2598-606. Epub
- 2020/10/10. https://doi.org/10.3201/eid2611.202263. PubMed PMID: 33035448; PubMed Central 1210
- PMCID: 7588541. 1211
- Bender JK, Brandl M, Höhle M, Buchholz U, Zeitlmann N. Analysis of Asymptomatic and 1212
- Presymptomatic Transmission in Sars-Cov-2 Outbreak, Germany, 2020. Emerging infectious 1213
- 1214 diseases. 2021;27(4):1159-63. Epub 2021/02/18. https://dx.doi.org/10.3201%2Feid2704.204576.
- 1215 PubMed PMID: 33600301.
- 1216 Zhang W. Estimating the Presymptomatic Transmission of Covid19 Using Incubation Period
- 1217 and Serial Interval Data. bioRxiv [Preprint]. 2020. https://doi.org/10.1101/2020.04.02.20051318.
- Tindale LC, Stockdale JE, Coombe M, Garlock ES, Lau WYV, Saraswat M, et al. Evidence 1218 170.
- 1219 for Transmission of Covid-19 Prior to Symptom Onset Elife. 2020;9. Epub 2020/06/23.
- 1220 https://doi.org/10.7554/elife.57149. PubMed PMID: 32568070; PubMed Central PMCID: 7386904.
- 1221 Tan J, Ge Y, Martinez L, Sun J, Li C, Westbrook A, et al. Transmission Roles of 171.
- Symptomatic and Asymptomatic Covid-19 Cases: A Modeling Study. medRxiv [Preprint]. 1222
- 2021:2021.05.11.21257060. https://doi.org/10.1101/2021.05.11.21257060. 1223
- 1224 Sun K, Wang W, Gao L, Wang Y, Luo K, Ren L, et al. Transmission Heterogeneities,
- 1225 Kinetics, and Controllability of Sars-Cov-2. Science. 2021;371(6526). Epub 2020/11/26.
- 1226 https://doi.org/10.1126/science.abe2424. PubMed PMID: 33234698; PubMed Central PMCID:
- 1227 7857413.
- Ren X, Li Y, Yang X, Li Z, Cui J, Zhu A, et al. Evidence for Pre-Symptomatic Transmission 1228 173.
- 1229 of Coronavirus Disease 2019 (Covid-19) in China. Influenza Other Respir Viruses. 2021;15(1):19-26.
- 1230 Epub 2020/08/09. https://doi.org/10.1111/irv.12787. PubMed PMID: 32767657; PubMed Central
- 1231 PMCID: 7436222.
- 1232 174. Peak CM, Kahn R, Grad YH, Childs LM, Li R, Lipsitch M, et al. Individual Quarantine
- Versus Active Monitoring of Contacts for the Mitigation of Covid-19: A Modelling Study. Lancet 1233
- 1234 Infect Dis. 2020;20(9):1025-33. Epub 2020/05/24. https://doi.org/10.1016/s1473-3099(20)30361-3.
- 1235 PubMed PMID: 32445710; PubMed Central PMCID: 7239635.
- 1236 Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A, Singer BH, et al. The 175.
- 1237 Implications of Silent Transmission for the Control of Covid-19 Outbreaks. Proc Natl Acad Sci U S

- 1238 A. 2020;117(30):17513-5. Epub 2020/07/08. https://doi.org/10.1073/pnas.2008373117. PubMed
- 1239 PMID: 32632012; PubMed Central PMCID: 7395516.
- 1240 176. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal Dynamics in Viral
- 1241 Shedding and Transmissibility of Covid-19. Nat Med. 2020;26(5):672-5. Epub 2020/04/17.
- 1242 <u>https://doi.org/10.1038/s41591-020-0869-5</u>. PubMed PMID: 32296168.
- 1243 177. Emery JC, Russell TW, Liu Y, Hellewell J, Pearson CA, Group CC-W, et al. The
- 1244 Contribution of Asymptomatic Sars-Cov-2 Infections to Transmission on the Diamond Princess
- 1245 Cruise Ship. Elife. 2020;9. Epub 2020/08/25. <a href="https://doi.org/10.7554/elife.58699">https://doi.org/10.7554/elife.58699</a>. PubMed PMID:
- 1246 32831176; PubMed Central PMCID: 7527238.
- 1247 178. Chun JY, Baek G, Kim Y. Transmission Onset Distribution of Covid-19. Int J Infect Dis.
- 2020;99:403-7. Epub 2020/08/11. <a href="https://doi.org/10.1016/j.ijid.2020.07.075">https://doi.org/10.1016/j.ijid.2020.07.075</a>. PubMed PMID:
- 1249 32771633; PubMed Central PMCID: 7409940.
- 1250 179. Bushman M, Worby C, Chang HH, Kraemer MUG, Hanage WP. Transmission of Sars-Cov-2
- before and after Symptom Onset: Impact of Nonpharmaceutical Interventions in China. Eur J
- Epidemiol. 2021;36(4):429-39. Epub 2021/04/22. <a href="https://doi.org/10.1007/s10654-021-00746-4">https://doi.org/10.1007/s10654-021-00746-4</a>.
- 1253 PubMed PMID: 33881667; PubMed Central PMCID: 8058147.
- 1254 180. Chau NVV, Thanh Lam V, Thanh Dung N, Yen LM, Minh NNQ, Hung LM, et al. The
- Natural History and Transmission Potential of Asymptomatic Sars-Cov-2 Infection. Clin Infect Dis.
- 1256 2020. <a href="https://doi.org/10.1093/cid/ciaa711">https://doi.org/10.1093/cid/ciaa711</a>.
- 1257 181. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative
- Rate of Reverse Transcriptase Polymerase Chain Reaction-Based Sars-Cov-2 Tests by Time since
- Exposure. Ann Intern Med. 2020. Epub 2020/05/19. <a href="https://doi.org/10.7326/M20-1495">https://doi.org/10.7326/M20-1495</a>. PubMed
- 1260 PMID: 32422057; PubMed Central PMCID: 7240870.
- 1261 182. Qiu X, Nergiz AI, Maraolo AE, Bogoch, II, Low N, Cevik M. The Role of Asymptomatic and
- 1262 Pre-Symptomatic Infection in Sars-Cov-2 Transmission-a Living Systematic Review. Clin Microbiol
- 1263 Infect. 2021;27(4):511-9. Epub 20210121. <a href="https://doi.org/10.1016/j.cmi.2021.01.011">https://doi.org/10.1016/j.cmi.2021.01.011</a>. PubMed
- 1264 PMID: 33484843; PubMed Central PMCID: 7825872.
- 1265 183. Goguet E, Powers JH, III, Olsen CH, Tribble DR, Davies J, Illinik L, et al. Prospective
- 1266 Assessment of Symptoms to Evaluate Asymptomatic Sars-Cov-2 Infections in a Cohort of Health
- 1267 Care Workers. Open Forum Infectious Diseases. 2022;9(3):ofac030.
- 1268 <u>https://doi.org/10.1093/ofid/ofac030</u>.
- 1269 184. Madewell ZJ, Yang Y, Longini IM, Jr, Halloran ME, Dean NE. Household Transmission of
- 1270 Sars-Cov-2: A Systematic Review and Meta-Analysis. JAMA Network Open. 2020;3(12):e2031756-
- e. <a href="https://doi.org/10.1001/jamanetworkopen.2020.31756">https://doi.org/10.1001/jamanetworkopen.2020.31756</a>.
- 1272 185. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic Transmission of Sars-
- 1273 Cov-2 Singapore, January 23-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):411-5.
- 1274 Epub 2020/04/10. http://dx.doi.org/10.15585/mmwr.mm6914e1. PubMed PMID: 32271722; PubMed
- 1275 Central PMCID: 7147908
- 1276 186. Hoffmann F, Eggers D, Pieper D, Zeeb H, Allers K. An Observational Study Found Large
- 1277 Methodological Heterogeneity in Systematic Reviews Addressing Prevalence and Cumulative
- 1278 Incidence. J Clin Epidemiol. 2020;119:92-9. Epub 20191203.
- 1279 <a href="https://doi.org/10.1016/j.jclinepi.2019.12.003">https://doi.org/10.1016/j.jclinepi.2019.12.003</a>. PubMed PMID: 31809847.

- 1280 187. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and Immunological
- Assessment of Asymptomatic Sars-Cov-2 Infections. Nat Med. 2020. Epub 2020/06/20. 1281
- 1282 https://doi.org/10.1038/s41591-020-0965-6. PubMed PMID: 32555424.
- Karim SSA, Karim OA. Omicron Sars-Cov-2 Variant: A New Chapter in the Covid-19 1283
- 1284 Pandemic. Lancet. 2021;398(10317):2126-8. Epub 20211203. https://doi.org/10.1016/s0140-
- 6736(21)02758-6. PubMed PMID: 34871545; PubMed Central PMCID: 8640673. 1285
- Sharma RP, Gautam S, Sharma P, Singh R, Sharma H, Parsoya D, et al. Clinico 1286
- 1287 Epidemiological Profile of Omicron Variant of Sars Cov2 in Rajasthan. medRxiv [Preprint].
- 2022:2022.02.11.22270698. https://doi.org/10.1101/2022.02.11.22270698. 1288
- 1289 190. Brandal LT, MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U, et al. Outbreak Caused by
- the Sars-Cov-2 Omicron Variant in Norway, November to December 2021. Euro Surveill. 1290
- 1291 2021;26(50). https://doi.org/10.2807/1560-7917.es.2021.26.50.2101147. PubMed PMID: 34915975;
- 1292 PubMed Central PMCID: PMC8728491.
- The Guardian Dismay as Funding for Uk's 'World-Beating' Covid Trackers Is Axed 1293
- 1294 12.03.2022 [Access Date: 17.03.2022]. Available from:
- https://www.theguardian.com/world/2022/mar/12/dismay-as-funding-for-uks-world-beating-covid-1295
- trackers-is-axed. 1296
- Acknowledgements 1298
- 1299 We are very grateful to Dianne Egli-Gany, Michel J. Counotte, Stefanie Hossmann who were part of
- our original core team of reviewers and contributed to the first three versions of this living systematic 1300
- review. 1301

- Author contributions 1302
- Conceptualization: Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Nicola Low 1303
- 1304 Data Curation: Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Hira Imeri, Lucia Araujo-
- 1305 Chaveron, Ingrid Arevalo-Rodriguez, Agustín Ciapponi, Muge Cevik, Muhammad Irfanul Alam,
- 1306 Kaspar Meili, Eric A. Meyerowitz, Nirmala Prajapati, Xueting Qiu, Aaron Richterman, William
- 1307 Gildardo Robles-Rodríguez, Shabnam Thapa, Ivan Zhelyazkov.
- 1308 Data extraction: Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Eric A. Meyerowitz,
- 1309 Aaron Richterman, Nirmala Prajapati, William Gildardo Robles-Rodríguez, Nicola Low
- 1310 Risk of Bias assessment: Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Ingrid Arevalo-
- 1311 Rodriguez, Anthony Hauser, Aaron Richterman, Nirmala Prajapati, William Gildardo Robles-
- Rodríguez, Nicola Low 1312
- Formal Analysis: Leonie Heron, Georgia Salanti, Nicola Low 1313
- Methodology: Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Anthony Hauser, Georgia 1314
- 1315 Salanti, Nicola Low
- Project Administration: Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Hira Imeri 1316
- **Supervision:** Georgia Salanti, Nicola Low 1317
- Validation: Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Hira Imeri, Lucia Araujo-1318
- 1319 Chaveron, Ingrid Arevalo-Rodriguez, Agustín Ciapponi, Muge Cevik, Muhammad Irfanul Alam,
- 1320 Kaspar Meili, Eric A. Meyerowitz, Nirmala Prajapati, Xueting Qiu, Aaron Richterman, William
- 1321 Gildardo Robles-Rodríguez, Shabnam Thapa, Ivan Zhelyazkov, Anthony Hauser, Nicola Low

- 1322 Writing-Original Draft: Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Nicola Low Writing- review & editing: Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Hira Imeri, 1323 1324 Lucia Araujo-Chaveron, Ingrid Arevalo-Rodriguez, Agustín Ciapponi, Muge Cevik, Muhammad 1325 Irfanul Alam, Kaspar Meili, Eric A. Meyerowitz, Nirmala Prajapati, Xueting Qiu, Aaron Richterman, 1326 William Gildardo Robles-Rodríguez, Shabnam Thapa, Ivan Zhelyazkov, Anthony Hauser, Georgia 1327 Salanti, Nicola Low. Funding 1328 1329 Funding was received from the Swiss National Science Foundation (320030 176233, to NL), <a href="http://www.snf.ch/en/Pages/default.aspx">http://www.snf.ch/en/Pages/default.aspx</a>; European Union Horizon 2020 research 1330 1331 and innovation programme (101003688, to NL), https://ec.europa.eu/programmes/horizon2020/en; Swiss government excellence Scholarship (2019.0774, to 1332 1333 DBG https://www.sbfi.admin.ch/sbfi/en/home/education/scholarships-and-grants/swiss-governmentexcellence-scholarships.html and the Swiss School of Public Health Global P3HS stipend (to 1334 1335 DBG), https://ssphplus.ch/en/globalp3hs/. The funders had no role in study design, data collection and analysis, decision to publish, or 1336 1337 preparation of the manuscript Competing interest statement 1338 NL is an academic editor at PLOS Medicine, received the grant funding from the organisations 1339 declared above, is a member of the Swiss National COVID-19 Science Task Force, and is on the 1340 scientific board of Sefunda, a start-up company that develops point-of-care diagnostics for sexually 1341 transmitted infections. 1342 1343 DBG receives funding from the organisations declared above. 1344 AMI, LH, HI receive salary support from the grants to NL from the Swiss National Science Foundation 320030 176233, and/or European Union H2020 101003688. 1345 1346 **Supporting Information** S1. PRISMA Checklist 1347 1348 S1 Text. Search strings 1349 S2 Text. Risk of Bias tool 1350 S1 Appendix. Data extraction forms 1351 S2 Appendix. Analysis of other systematic reviews on asymptomatic SARS-CoV-2 1352 S1 Table. Studies included in version 3.0 and excluded in version 4.0 of the living systematic review S2 Table. Characteristics of studies reporting on proportion of asymptomatic SARS-CoV-2 infections 1353 (review question 1 and question 2) 1354 1355 S3 Table. Location of studies contributing data to review question 1 1356 S4 Table. Subgroup analysis according to risk of bias S5 Table. Characteristics of mathematical modelling studies 1357
- S1 Fig. Flowchart of identified, excluded, and included records as of 6 July 2021
- 1359 S2 Fig. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection, stratified by
- 1360 study design.

1361 S3 Fig. Risk of bias assessment of studies in question 1 and 2 S4 Fig. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection by date of 1362 publication. 1363 1364 S5 Fig. Assessment of credibility of mathematical modelling studies.